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Abstract 
 
Hearing loss is one of the most common birth defects in developed countries. Approximately one/two 
in 1000 newborns are diagnosed with bilateral permanent sensorineural hearing loss.  
Hereditary hearing loss can be syndromic (about 25%), in which deafness is associated with other 
signs and/or symptoms, and non-syndromic (about 75%), in which no other clinical features are 
present. 
Non-syndromic hearing loss (NSHL) is characterized by a vast genetic heterogeneity with more than 
160 loci described in humans and 100 genes so far identified. NSHL generally follows simple 
Mendelian inheritance and is predominantly transmitted as an autosomal recessive trait (75-80%), 
although other modes of inheritance are possible: autosomal dominant (20%), X-linked (2-5%) and 
mitochondrial (1%).  
Given the high genetic heterogeneity of HL, tests based on NGS technologies are rapidly replacing 
many single-gene Sanger sequencing tests, due to their technical limits and higher costs. 
The aim of this work was translational, with the goal to develop advanced molecular tools, with high 
diagnostic rate, and to investigate the genetic bases of NSHL in a population of Caucasian individuals, 
mainly of pediatric age. 
A customized NGS targeted panel of 59 genes, strongly associated, in Caucasians, with NSHL or 
with SHL, which onset is usually characterized by isolated deafness (i.e. Pendred and Usher 
syndrome), was designed and developed.  
The Ion Torrent PGMTM  platform and a customized bioinformatics pipeline have been used for the 
analysis of DNA samples collected from clinically highly selected subjects with a previous negative 
test for the frequently mutated GJB2 gene.  
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A series of 78 cases has undergone a complete study; an etiological diagnosis has been established 
for 34 of these subjects, with an overall diagnostic yield of 43.6%. 
For each tested subject, an average depth of coverage of 249 X in the analyzed sequences and a mean 
of 499 variants were obtained. 
Likely causative identified variants were located in the following 20 genes: CDH23, GJB2, COCH, 
MYO7A, ADGRV1, EYA4, OTOG, SLC17A8, TMPRSS3, ACTG1, CEACAM16, COL11A2, GJB3, 
KCNQ4, MYH9, MYO6, PTPRQ, SLC26A4, STRC, TMC1. 
The most frequently mutated gene in our cohort was CDH23, which, even in our cases, accounted 
both for NSHL and Usher syndrome type 1 phenotypes.  
A novel EYA4 mutation, identified in two related subjects with post-lingual progressive deafness, was 
found to co-segregate in two individuals of the same family, with a Waardenburg syndrome 
phenotype, due to a novel PAX3 gene mutation.  
All the identified variants were collected in an in-house database that proved an invaluable tool for 
the identification of recurrent variants or possible alignment errors, and for further stratification and 
correlation between genotype and phenotype. 
In conclusion, the targeted gene-panel we have developed, in combination with the in-house 
bioinformatics pipeline, is a proven sensitive diagnostic tool capable of providing an extremely 
competitive diagnostic yield. 
Our work further demonstrates the importance of integrating the power of NGS technology and data 
process with the fundamental role of a strong clinical evaluation in keeping with what is expected 
from modern medicine. 
 
 
 
 
IX 
 
Riassunto 
 
Nei paesi sviluppati, l’ipoacusia rappresenta uno dei principali deficit presenti alla nascita; circa 1/2 
su 1000 neonati vengono diagnosticati con una perdita uditiva neurosensoriale bilaterale permanente. 
L’ipoacusia ereditaria può essere sindromica, in circa il 25% dei casi, in cui la sordità è associata ad 
altri segni e/o sintomi e non sindromica (circa il 75%), in cui non sono presenti altre caratteristiche 
cliniche. 
L’ipoacusia neurosensoriale non sindromica è caratterizzata da una vasta eterogeneità genetica con 
più di 160 loci descritti nell'uomo e circa 100 geni finora identificati. Tale ipoacusia viene 
prevalentemente ereditata in modo autosomico recessivo (75-80%), poi autosomico dominante (20%) 
e in rari casi è ereditata per via X-linked (2-5%) o mitocondriale (1%). 
Considerando l'elevata eterogeneità dei geni associati ad ipoacusia, le tecnologie NGS stanno 
rapidamente sostituendo il sequenziamento Sanger su singolo gene, a causa dei limiti tecnici e dei 
costi di quest’ultimo. 
Lo scopo di questo lavoro è stato traslazionale, ovvero sviluppare uno strumento molecolare avanzato, 
con un elevato rate diagnostico, per indagare le basi genetiche dell’ipoacusia non sindromica in una 
popolazione di individui caucasici, soprattutto di età pediatrica.  
Allo scopo, è stato quindi disegnato un pannello genico comprendente 59 geni fortemente associati, 
nei Caucasici, ad ipoacusia non sindromica o ad ipoacusia sindromica, in particolare includendo 
quelle condizioni in cui la sordità insorge prima degli altri sintomi, come apparentemente isolata 
(sindrome di Pendred e sindrome di Usher). 
L’analisi NGS è stata condotta sulla piattaforma Ion Torrent PGMTM ed è stata sviluppata una pipeline 
di analisi dati per ottimizzare la chiamata delle varianti, utilizzando criteri di filtraggio ad hoc. 
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In totale sono stati analizzati 78 soggetti, caratterizzati clinicamente e testati per le mutazioni nel gene 
GJB2 e le delezioni del gene GJB6, risultando negativi. 
Per 34 soggetti sui 78 analizzati è stato possibile ottenere una diagnosi molecolare, consentendo una 
resa diagnostica complessiva del 43,6%. 
Per ciascun soggetto testato è stata ottenuta una copertura media di 249X e una media di 499 varianti. 
Le varianti possibilmente causative identificate sono state localizzate nei geni: CDH23, GJB2, 
COCH, MYO7A, ADGRV1, EYA4, OTOG, SLC17A8, TMPRSS3, ACTG1, CEACAM16, COL11A2, 
GJB3, KCNQ4, MYH9, MYO6, PTPRQ, SLC26A4, STRC, TMC1. 
Nella coorte di soggetti analizzati il gene più frequentemente mutato è stato CDH23, identificato sia 
in soggetti con ipoacusia non sindromica che in un bambino con sindrome di Usher di tipo 1. 
E’ stata inoltre identificata una nuova mutazione nel gene EYA4, presente in due soggetti correlati 
con sordità progressiva post-linguale; tale variante è stata trovata anche in altri due soggetti della 
stessa famiglia, i quali presentavano un fenotipo di sindrome di Waardenburg e nei quali è stata 
identificata una nuova variante nel gene PAX3. 
Tutte le varianti identificate sono state raccolte in un database interno, che costituisce uno strumento 
prezioso per identificare le varianti ricorrenti, eventuali errori di allineamento e per un’ulteriore 
stratificazione e correlazione tra genotipo e fenotipo. 
In conclusione, il pannello genico sviluppato, in combinazione con una pipeline bioinformatica ad 
hoc, si è dimostrato uno strumento diagnostico molto sensibile ed in grado di fornire diagnosi 
eziologica con una resa diagnostica estremamente competitiva. 
Questo lavoro dimostra l’importanza di coniugare le nuove potenti tecnologie di analisi genomica 
NGS e di processamento dei dati con un’accurata caratterizzazione clinica, in linea con le richieste 
della moderna medicina.
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1. INTRODUCTION 
 
1.1 Anatomy and physiology of the ear 
 
The auditory system is composed by three parts, illustrated Figure 1.1, that are necessary to proper 
transduction of the sounds: i) The external ear that comprises the auricle and the external auditory 
canal (EAC). The EAC directs sounds from the auricle to the tympanic membrane. The external ear 
alters sound wave amplitudes and provides a mechanism for amplification of different sounds within 
the frequencies of human speech. The sound waves are translated into mechanical stimuli in the form 
of vibrations, which are transmitted through the middle ear. ii) The middle ear is an air-filled space 
that consists of the tympanic membrane, tympanic cavity, ossicles and associated muscles. It is 
connected to the back of the nose by the Eustachian tube. The three ossicles (malleus, incus and 
stapes), located between the tympanic membrane and the cochlea, conduct sound from the tympanic 
membrane towards the cochlea.  
iii) The inner ear comprises the cochlea, responsible for hearing, and the vestibular system, 
responsible for balance [1]. 
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Figure 1.1 Anatomy of the ear; it is divided in three part: the outer ear, middle ear, inner ear.  
 
1.1.1 The cochlea 
 
The cochlea is a bony coiled tube shaped like a snail shell, as shown in Figure 1.2, filled with fluid 
called perilymph. This shell is divided in three compartments, called scalae: the scala vestibuli, the 
scala media, filled with endolymph, and the scala tympani; the basilar membrane divided the scala 
timpani from scala media, while Reissner’s membrane divide scala media from scala vestibuli. 
The scala media contains the cochlear sensory epithelium, the organ of Corti, which sits on top of the 
basilar membrane and is ultimately responsible for the mechano-electrical transduction of sound. The 
organ of Corti is composed of two classes of hair cell, inner and outer, with distinct functions and 
supporting cells. 
Information about the acoustic environment (speech, music or other sounds in the outside world) is 
relayed primarily by the electrical signals of inner hair cells (IHCs), whereas the main task of outer 
hair cells (OHCs) is to boost the stimulus by electromechanical feedback [2].  
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Sound-induced mechanical vibration of the middle ear is transmitted to the cochlea, generating 
movements of its associated fluids. As a consequence, deflection of the basilar membrane activates 
the sensory cells that transduce the mechanical stimulations into electrical signals, in particular three 
rows of OHCs amplify the vibrations; then the mechanical signals are transferred onto IHCs, which 
transmit the information to afferent neurons. Hair cells at the base of the cochlea respond to the 
highest frequencies and those at the apex to the lowest. Sound frequencies are therefore relayed to 
the nervous system as a tonotopic map [3]. 
 
 
Figure 1.2 A) Schematic representation of the cochlea and the vestibule. B) A cross-section of the cochlear duct presents 
the scala media, scala tympani and scala vestibule, as well as the tectorial membrane (TM) over the organ of Corti. C) 
An enlargement of the organ of Corti, showing three rows of OHCs and one row of IHCs, flanked by various types of 
supporting cells. Figure modified from Dror et al, 2010 [4]. 
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1.1.2 The Vestibular system 
 
The vestibular organ consists of three semicircular canals, and two satellite organs: the utricle and 
saccule, as illustrated in Figure 1.3. The vestibular system is the sensory system that has a primary 
role in the sense of balance and is responsible of movement coordination in the spatial orientation. 
Receptor organs in the semicircular canals respond to angular acceleration while receptor organs in 
the utricle and saccule respond to linear acceleration and static tilt. 
 
 
 
Figure 1.3 Schematic representation of the vestibular system. Figure modified from Zeng et al, 2011 [5] 
 
1.2 Hearing and hearing loss 
 
Normal mammalian auditory functions rely on two categories of function: mechanical and 
electrochemical. Malfunction of either of these auditory processing components results in hearing 
loss (HL), with considerably different molecular etiologies, clinical presentations, and possible 
appropriate management. 
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Hearing loss is clinically classified as conductive, definition which refers to a malfunction of the 
mechanical components of the auditory processing, sensorineural referring to malfunctions of the 
electrochemical or neurological components, and mixed when different aspects are present at the 
same time. Conductive hearing loss typically results from middle ear pathology, as tympanic 
membrane perforation, ossicular discontinuity or fixation, or middle ear infections, that are often 
amenable to improvement with either amplification (i.e. hearing aids) or surgical procedures. 
Sensorineural hearing loss (SNHL), on the other hand, can result from malfunction anywhere along 
the auditory pathway, from the hair cell to higher-order central auditory processing loci [6]. SNHL 
can be congenital or develop at a later stage in life. 
Hearing loss is the most common birth defect and sensory disorder in the industrialized countries, 
with a prevalence of two to four in 1,000 newborns [7]. It can be caused by genetic factors (60-70% 
of cases), or by environmental causes as trauma, medications, medical problems, environmental 
exposure and Cytomegalovirus infection, that is the most common non-genetic cause of HL in 
children and can manifest in early childhood, can be unilateral or bilateral and is often progressive 
[8]. 
Newborn screening for hearing defects has an important role in treatment and rehabilitation strategies, 
such as cochlear implantation. Early etiological diagnosis in newborns and infants allows the effective 
monitoring of possible complications and can indicate which therapy is most suitable and appropriate. 
It is also necessary for a more accurate genetic counseling for parents and other family members.  
 
1.2.1 Measuring the hearing threshold 
 
Audiological diagnosis consists of three phases: identification of subjects at risk, definition of hearing 
loss and/or subjects’ features, verification of appropriateness of diagnosis itself and rehabilitation 
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program. Strategies and methods of audiological diagnosis include an integration of data coming from 
objective methods with clinical and behavioral data [9].  
The hearing ability is tested by stimulating the auditory system with a sound. This can be obtained 
through air conduction, which tests all the components of the auditory system, or through bone 
conduction via a transmitter placed on the skull, which bypasses the outer and middle ear.  
A conductive hearing loss is suspected when the auditory response to air conduction is reduced but 
bone conduction is normal. However, SNHL is most likely if both air and bone conductions are 
reduced. 
The subjective test consists on response from the individual that must actively indicates which tones 
at fixed levels, that are presented, can listen. The test consists of presenting beeps as varying 
intensities for different test frequencies, recording at each frequency the lowest intensity at which 
there are responses from the listener. 
The response is represented on an audiogram that shows the hearing level in deciBels (dB) at multiple 
frequencies (Hz). The threshold audiogram produces a picture of how a person hears air-conducted 
signals, such as pure tones. 
Normal hearing frequencies range between 20 and 20,000 Hz, with speech perception that is around 
2,000 Hz. The normal speech perception audiogram has the shape of a banana, in which all the 
phonemes, or sounds of audible human language are represented; it is called “speech banana 
audiogram”, as reported in Figure 1.4. Those with a normal hearing can also hear sounds above this 
range, as well as high-frequency and low-frequency sounds. 
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Figure 1.4 Speech banana audiogram. In yellow is represented the audible phonemes and sound. On the X-Axis are 
plotted the frequencies, measured in Hz. On Y-axis is reported the loudness, expressed in db. On the right is reported the 
degree of hearing loss.  
 
Hearing loss can be described according to severity, depending on the auditory threshold: 0-20 dB is 
within normal limits, 21-40 dB: mild; 41-70 dB: moderate, 71-95 dB: severe , and ≥96 dB, profound 
[10]. Depending on the type of HL, a characteristic audiogram shape appears: high-frequency HL is 
described as “down-sloping”; low-frequency as “rising” and mid-frequency is “cookie-bite.”  
To obtain an objective audiogram profile, especially in young children or during the neonatal 
screening, different tests are available that should be used in combination. In particular: i) otoacoustic 
emissions (OAEs) measure the returned sound from the cochlear cells after a sound stimulation is 
sent to the cochlea. ii) Auditory brain stem responses (ABRs) measure the evoked potential generated 
by sound after it has been transduced into an electrical signal and is transmitted from the VIII cranial 
nerve to the brain. 
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In the context of permanent childhood hearing loss, early audiological diagnosis is a prerequisite for 
activation of an adequate rehabilitation program to prevent or limit the known effects that auditory 
deprivation determines on language development and cognitive skills in neonates. 
 
1.3 Hereditary Hearing Loss 
 
Hereditary hearing loss (HHL) is characterized by a vast phenotypic heterogeneity. The first human 
gene associated with deafness was GJB2 (Cx26, OMIM # 121011) in 1997 [11]. Even before the 
identification of the mutations in this gene, it was clear that a significant proportion of HL was 
hereditary and therefore due to gene mutations. Since the first gene discovered, great scientific 
advancements have been made and many genes now considered responsible of HL have been 
identified. 
So far 160 loci have been described in humans and 100 genes have been identified, distributed 
throughout the chromosomes, as reported in Figure 1.5 (Hereditary Hearing Loss Homepage; 
http://hereditaryhearingloss.org/ last accessed September 2017).  
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Figure 1.5 Chromosomal location of genes associated with hearing loss. Figure modified from Dror et al, 2010 [3]. 
 
The genes so far identified, encode a large variety of proteins with many functions in the inner ear, 
such as genes responsible for gene-regulation, fluid homeostasis, synaptic transmission and hair cell 
bundle morphology and development [12]. 
HHL can be syndromic hearing loss (SHL) in about 25% of cases, in which deafness is associated 
with other signs and/or symptoms, and non-syndromic (NSHL), in 75% of cases, in which there are 
no additional clinical abnormalities. 
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1.4 Syndromic Hearing Loss 
 
SHL is defined by the presence of HL associated with defects in many different organs, such as 
anomalies of the eyes, kidneys, the musculoskeletal and the nervous systems, as well as pigmentary 
disorders and other alterations, as shown in Figure 1.6 [13]. 
Among the well-known complex conditions involving HL, Pendred, Usher and Waardenburg 
syndromes are the most common ones [14]. In these conditions (mainly Pendred and Usher) the 
hearing loss often is present before the onset of the other clinical features, giving the impression of a 
non-syndromic form of deafness. Several genes associated with SHL are also involved in NSHL, as 
in the case of SLC26A4, whose mutations are responsible both of Pendred syndrome and DFNB4 
and hearing loss with Enlarged Vestibular Acqueduct (EVA syndrome). 
The complete list of known genes associated with SHL is reported in Appendix 1. 
 
 
 
Figure 1.6 Schematic representation of the different organs involved in SHL. F, female genitals; M, male genitals. 
Figure modified from Koffler et al. 2015 [13]. 
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1.4.1 Pendred Syndrome 
 
The estimated prevalence of Pendred syndrome is 7.5 per 100,000 newborns and it accounts for 
approximately 1 to 8% of the cases of congenital deafness; it is inherited as autosomal recessive. 
The audiological phenotype varies from mild to profound hearing loss with pre or post-verbal onset 
and a typically fluctuant and progressive course. A common feature among patients is an enlarged 
vestibular aqueduct (EVA). Pendred syndrome also features thyroid dysfunction, leading to 
hypothyroidism with euthyroid goiter and vestibular dysfunctions, demonstrated in approximately 
65% of affected individuals [13]. 
 
1.4.2 Usher Syndrome 
 
The prevalence of Usher syndrome ranges from 1/6,000 to 1/10,000. It is an autosomal recessive 
genetic disease with clinically and genetically heterogeneous characteristics. It is defined by 
congenital bilateral sensorineural deafness and a later onset of vision impairment, caused by retinitis 
pigmentosa. This syndrome is sub-classified into three clinical types, USH1, USH2, and USH3, based 
on the severity of the SNHL, the presence or absence of vestibular dysfunctions and the age at onset 
of retinitis pigmentosa [15]. 
 
1.4.3 Waardenburg syndrome 
 
Waardenburg syndrome (WS) is estimated to have a prevalence of 1/42,000 and is responsible for 1–
3% of all congenital HL cases [16]. 
It is characterized mostly by SNHL and pigmentation abnormalities that can occur in the eyes, hair, 
skin and the cochlear stria vascularis. Four clinical types of WS have been described (WS1–WS4).  
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WS type 1 and type 2 are the most frequent phenotypes distinguished by dystopia canthorum, which 
is present only in WS1. 
 
1.5 Genetics of non-syndromic hearing loss 
 
NSHL is genetically very heterogeneous, with more than associated 160 loci and 106 identified 
disease genes. It generally follows simple Mendelian inheritance and is more frequently autosomal 
recessive (75-80%), than autosomal dominant (20%), X-linked (2-5%) and in few cases (1%) NSHL 
is due to mitochondrial mutations [17]. The forms of NSHL inherited as autosomal dominant, also 
referred to as DFNA, are usually post-lingual and progressive, while autosomal recessive forms, 
referred to as DFNB, are more typically pre-lingual, severe to profound [18]. Until now 36 genes 
have been reported as responsible of autosomal dominant hearing loss, 65 of autosomal recessive and 
5 of X-linked hearing deficit (Hereditary Hearing Loss Homepage. http://hereditaryhearingloss.org/; 
last accessed October 2017). The complete gene-list is reported in Appendix 2.  
Despite the heterogeneity, defects at the DFNB1 locus, which contains the GJB2 gene (Cx26 OMIM 
#121011), and the structurally related GJB6 gene (Cx30 OMIM #204418), play a major role 
worldwide, although with a frequency of mutant alleles that varies between countries and even 
between regions of the same country [19].   
In Caucasian subjects with pre-lingual non-syndromic autosomal recessive hearing loss, it was 
estimated an average frequency of GJB2 mutations of 31.5% [20]. The most frequent GJB2 mutation 
in Caucasians is c.35delG, with a carrier rate of 1/30-1/35 in the general population of the 
Mediterranean area  [21].  
It was demonstrated that individuals homozygote for c.35delG have a more severe hearing loss with 
respect to those in which c.35delG co-segregates with other GJB2 mutations: c.[35delG]; 
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[358_360delGAG], c.[35delG]; [-23+1G>A], c.[35delG]; [269T>C], c.[35delG]; [109G>A] and that 
the specific genotype has a major impact on the degree of hearing impairment [22].  
In up to 50% of subjects with HL and heterozygotes for GJB2 mutation, a deletion of 309 kb 
del(GJB6-D13S1830) truncating the neighboring GJB6 gene was identified [23]. A rarer deletion of 
232kb del(GJB6-D13S1854), at the DFNB1 locus, was also found in trans with pathogenic GJB2 
mutations in affected subjects [24]. It was demonstrated that these deletions remove putative cis-
regulatory element upstream of GJB6 and down-regulate the region of location that impact on GJB2 
expression [25].  
Currently there is a general consensus on molecular analysis of DFNB1-related hearing loss (due to 
mutations in GJB2 and adjacent deletions in GJB6) as the first step in genetic testing for non-
syndromic hearing loss [26].  
 
1.6 Genetic testing for deafness 
 
HL is defined based on clinical presentation and age of onset; it is necessary to distinguish syndromic 
from non-syndromic forms, and performing the appropriate genetic test is of paramount importance. 
A genetic diagnosis in fact provides essential information on the nature of the hearing loss, on the 
prognosis as well as and on the best rehabilitation options for affected subject; it also offers the 
possibility of a precise genetic counseling for the parents and other family members. 
Conventional technologies for genetic testing, such as Sanger sequencing, are highly accurate and 
sensitive but are burdened by an extremely low throughput, which has represented a main obstacle to 
the expansion of testing. Sanger sequencing is useful to test one gene at a time and it is proven 
effective in cases in which a single gene, or a very limited number of genes, are held responsible of 
a certain phenotype such as a HL subtype. 
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In these instances, a screening by Sanger sequencing can be cost-effective. For example, sequencing 
GJB2 can identify the underlying etiology in 50% of subjects with congenital or pre-lingual, likely 
autosomal recessive, non-syndromic hearing loss. 
Modern NGS technologies, allowing massive parallel sequencing, enable simultaneous analysis of a 
large number of specific disease-genes, in case of a targeted multigene panel strategy, or even the 
entire coding sequences, in case of whole exome sequencing (WES). Analysis of the whole genome 
(WGS) has not yet entered the clinical arena. 
Genetic tests based on Next Generation Sequencing (NGS) technologies are currently rapidly 
replacing single gene-sequencing in the diagnostic setting. 
According to the ACMG practice guideline, the correct diagnostic workflow for Hearing Loss is to 
search for GJB2/GJB6 alterations as a first-tier test and then proceed to testing large targeted gene-
panels and  then go to WES and eventually WGS analysis [26]. 
 
1.7 Next-generation sequencing in hearing loss 
 
The crucial advantage of NGS technologies is the ability to address the problem of genetic 
heterogeneity in conditions that cannot be easily distinguished clinically [27]. This is very much the 
case of NSHL, in which many different genes are causally implicated and where it is very difficult to 
correlate pre-diagnostic hypotheses through clinical history and audiological data. A number of 
papers have  indeed reported very encouraging data on targeted gene panels and WES applied to the 
etiological diagnosis of hearing loss [28].  
Targeted NGS tests restrict sequencing to specific sets of genes, known as disease-causing or highly 
candidate as associated with hearing loss. Such tests, although as mentioned, limited to a certain set 
of genes can provide an excellent depth of coverage of the selected sequences assuring therefore the 
best analysis of these sequences.  
15 
 
There are different targeted NGS platform commercially available, that differ mainly on the library 
preparation method and on the sequencing chemistry. 
Library preparation can be performed with amplification method or solution capturing method. The 
main advantages of the first method, compared to the second one are the high multiplexing capacity 
and flexibility as it is easy to design and add more specific primers. However, the main disadvantages 
are the chemistry issues associated with PCR primers. For examples, PCR primers may not amplified 
the targeted region because of underlying SNPs [29], causing allele-drop-out, PCR primers may fail 
to amplify GC-rich region and often is difficult to design primers that can discriminate gene from 
pseudogene when they are highly homologous. 
A number of  Hearing Loss NGS studies been performed with targeted panels of different quality 
both in terms of analysis and number of examined genes have reported highly variable diagnostic  
yields [30] [31].  
Obviously Targeted NGS does not address the issue of detection of new genes which is instead a 
question that can be answered by WES, and finally by WGS. 
WES is also based one exon capture but does not depend on a list of genes involved in a specific 
disease process. Instead, WES seeks to evaluate all exons in the genome for variations. This approach 
can identify variants in known hearing loss–related genes and genes that have yet to be associated 
with hearing loss [26].  
WGS otherwise is not limited to screening exons and therefore has the potential to identify changes 
outside of exons that may be related to hearing loss. 
Depth of coverage and data interpretation are very important limits of WES and WGS due to the 
spreading of the sequencing capacity and the large amount of sequencing data to be analyzed. 
Furthermore, not all the genomic regions are efficiently captured and analyzed by current exon-
capture in WES or WGS approach. 
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Irrespective of the NGS strategy adopted of course,  large deletions and duplications, in addition to 
copy-number and structural variations, are not  be efficiently detected yet [32]. 
A recent study, performed in a large cohort of individuals from The Netherlands, revealed a diagnostic 
yield of WES targeting only HL related genes, of 33.5%; a comparable result to other studies 
performed with other massively parallel sequencing technologies in different populations [33].  
 
1.8 Using the Ion Torrent Platform 
 
1.8.1 Sequencing technology and workflow 
 
The Ion Torrent sequencing method, the only one not employing Sanger sequencing, represents an 
innovation within the innovative NGS technology. It in fact uses a new semiconductor chip, capable 
of directly translating chemical signals into digital information, without the use of light, which results 
in unprecedented speed, scalability and lower costs of sequencing.  
The Ion Torrent sequencing chemistry itself is remarkably simple. Naturally, a proton (H+) is released 
when a nucleotide is incorporated by the polymerase in the synthetizing DNA molecule, resulting in 
a detectable local change of pH. Each micro-well of the Ion Torrent semiconductor-sequencing chip 
contains approximately one million copies of a DNA molecule. The Ion Personal Genome Machine 
(PGM™) sequencer sequentially floods the chip with one nucleotide after another (solutions of native 
dATP, dCTP, dGTP, dTTP, respectively). If a nucleotide complements the sequence of the DNA 
molecule in a particular micro-well, it will be incorporated and H+ are released. The change of pH is 
detected by the ion sensor and converted to a voltage and to a digital information. If there are two 
identical bases on the DNA strand, the voltage is double, and the chip records two identical bases. If 
the next nucleotide that floods the chip is not a match, no voltage change is recorded and no base is 
called (Figure 1.7) [34]. After each dNTP flow, a wash flow is performed to fully eliminate the 
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previous nucleotide prior to attempting the next. The Ion Torrent PGMTM (ThermoFisher 
SCIENTIFIC) workflow consists on the steps illustrated in Figure 1.8. 
 
 
 
Figure 1.7 Overview of Ion Torrent sequencing process. A) The sequencing chemistry configuration, with templated DNA 
bead (brown sphere) deposited in a well above the sensor. As a specific dNTP flows into the well, H+ is released if it is 
incorporated as the next base the resulting H+ release is converted into a voltage change. B) These pH signals are 
sampled in a plot. (C) The incorporation signals for each flow is converted in a plot called ionogram. Figure modified 
from Merriman et al. 2012 [34]. 
 
 
Figure 1.8 Ion torrent process overview. 
 
18 
 
1.8.2 Library preparation 
 
Genomic DNA or FFPE DNA, or reverse-transcribed RNA are PCR amplified with Ion AmpliSeq™ 
Library Kit 2.0, using specific primer-pairs designed with Ion Ampliseq Designer or commercially 
available panels.  
The amplicons are partially digested and phosphorylated with FuPa reagents, and then flanked with 
the Ion Torrent Barcode adapters at 5’ and with P1 adapters at 3’ end. The libraries are quantified and 
then combined together according to the manufacturer’s instruction. Figure 1.9 represents the entire 
process of library preparation. 
 
 
Figure 1.9 Schematic representation of library preparation process. Figure modified from Ion AmpliSeq™ Library Kit 
2.0 User Guide. 
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1.8.3 Template preparation/amplification 
 
The library amplicons are then clonally amplified onto the proprietary Ion Sphere™ particles (ISP) 
according to the manufacturer’s instruction. Clonal amplification is accomplished by emulsion PCR 
(emPCR) performed in the Ion PGM™ One Touch 2 Instrument and illustrated in Figure 1.10. The 
ISP-beads coated with complementary primers are mixed with a dilute aqueous solution, containing 
the amplicons to be sequenced along with the necessary PCR reagents. This solution is then mixed 
with oil to form an emulsion of microdroplets. The ratio of beads and amplicons is kept low enough 
so that each microdroplet ideally contains only one of each.  
P1 adapters ligated to amplicons are complementary to the sequence coated to the beads, so after a 
denaturation step, the ssDNA fragment is formed, and then the annealing and extension phase are 
necessary to synthesize the complementary fragment, which will be further denatured and so on until 
the PCR reaction ends. At the end, each bead contains ssDNA amplicons. 
 
 
 
Figure 1.10 Schematic representation of emPCR. A) The tube contains a mixture of beads, primer, template, dNTPs and 
polymerase. B) The amplicon binds to the bead via the P1 adapter, and then is clonally amplified. The double strand 
amplicon is then denaturated to form a single strand amplicon. C) Each bead contains single strand amplicon. Figure 
modified from Metzker 2010 [35]. 
 
The Ion Sphere™ Quality Control assay with the Qubit® 2.0 Fluorometer is then performed to 
evaluate the quality of the templated-ISP and to calculate the percentage of ISPs that correctly bound 
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to the DNA amplicons. The assay measures the fluorescence of template-positive ISPs labeled with 
two fluorophores: Alexa Fluor® 488 and Alexa Fluor® 647.  The probe labeled with Alexa Fluor® 
488 anneals to primer B sites, while the probe labeled with Alexa Fluor® 647 anneals to primer A 
sites, as shown in Figure 1.11. 
 
 
Figure 1.11  Schematic illustration of the Alexa Fluor® 488 and Alexa Fluor® 647, which anneal to the amplicon to 
primer B sites and to primer A sites, respectively. Figure modified from Ion PGM™ Hi‑Q™ OT2 Kit User Guide.  
 
The ratio of the Alexa Fluor® 647 fluorescence (templated ISPs) to the Alexa Fluor® 488 
fluorescence (all ISPs present) yields the percentage of templated ISPs and it is calculated with the 
Qubit® Easy Calculator, reported in Figure 1.12. 
The templated-ISPs were then enriched using the Ion OneTouch™ ES instrument, using Dynabeads® 
MyOne™ Streptavidin C1, that ligate the biotinylated templated-ISP.  
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Figure 1.12 Excel file template used for calculation of the percentage of template ISPs. RFU: relative fluorescence unit. 
The value of percentage of template ISP appears in column G (#DIV/0!) after entering the RFU values, using a trademark-
masked formula. Figure modified Ion PGM™ Hi‑Q™ OT2 Kit User Guide. 
 
1.8.4 Sequencing 
 
The enriched templated-ISPs are loaded on the Ion chip, which is placed on the PGM instrument, to 
perform the sequencing run. The chip capacity varies between different types of chips and amplicons 
read-length determines the sequence run-time. Each chip produce different amount of output in term 
of bp, and consequently numbers of reads, as reported in Table 1.1. 
 
Table 1.1 Ion Torrent chip capacity. Mb: Megabases; Gb: Gigabases; hr: hours. 
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1.8.5 Data analysis 
 
The PGM generates DAT files of electrical signals' raw traces that are the conversion of the raw pH 
value in a well, to a digital representation of the voltage. This measure is then converted in a graph 
(ionogram) that represents the base per position image. These raw data are transferred to the Torrent 
Server for analysis pipeline processing, that is performed by the Ion Torrent Suite Software. 
The main steps are the follow: i) the signal processing-step converts the raw traces into a single 
number per flow per well; ii) The raw Ion signals are then converted to base calls and stored as 
unaligned BAM file, indexed with a BAI file; iv) The BAM file is passed to TMAP (Torrent Mapping 
Alignment Program) for alignment. 
The Torrent Suite software produce a summary run report that contains the statistics and quality 
metrics of the run, as illustrated in Figure 1.13. In particular, it contains information on the chip 
loading, on the total bases and on the key-signal that is a run-quality parameter. The ISP summary 
table reports the quality of the ISP loaded. It is also reported the metric of the reads length. For each 
barcoded-subjects the following information are displayed: the number of total bases, the called bases 
with a predicted quality of Q20, that is reported on the Phred scale, defined as -10×log10 (error 
probability) and corresponds to a predicted error rate of one percent; the number of total reads and 
the mean fragment read length. 
Test fragments (TFs) provide information about the performance of the experiment; in particular, 
TF_C evaluates the sequencing run, while the TF_1 evaluates the OT2 process. 
Other information contained in the run report are regarding reads’ alignments to reference sequence 
of Homo sapiens (hg19/GRCh37) such the aligned and unaligned bases, the aligned and unaligned 
reads. 
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The Raw Accuracy graph plots percent accuracy for each position in an aligned sequence. The 
information regarding the alignment quality (AQ17, AQ20 and perfect) are represented in table and 
in a color-plot that illustrate different Phred quality scores (Figure 1.13). 
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Figure 1.13 Example of summary run report. A) ISP density plot and information about the chip loading. B) ISP summary. 
C) Read-length with mean, median, mode values. D) Key-signal plot. E) Chip-well details and library ISP details. F) 
Barcoded-samples information on total reads and reads-length. G) Test-fragments data.  H) Alignment summary on hg19.  
I) Bases alignment accuracy plot. J) Alignment quality table. K) Plot of different Phred Quality score for read length. 
25 
 
The Coverage Analysis Report, produced by the specific plug-in, consists of a collection of summary 
statistics and graphical representations of the reads coverage for each barcoded sample. In Figure 
1.14 is reported the summary of the plug-in results that contains the number of mapped reads, the 
percentage of the reads mapped on target, the mean depth and the uniformity of coverage expresses 
as percentage.  
 
 
 
Figure 1.14 Example of coverage analysis plug-in summary report. 
 
The Variant Caller plug-in, Figure 1.15, produces the files necessary to further analysis of the 
variants. In particular the Variant Call Format (.vcf), contains the list of the variants identified for 
each subject (Single Nucleotide Variants and small insertions/deletions), and is associated with its 
index file (.vcf.tbi.). 
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Figure 1.15 Example of Variant caller plug-in summary report. 
 
1.9       Variants annotation 
 
The list of variants obtained from Variant Caller plug-in must be annotated. Different tools are 
available and the most frequently used is ANNOVAR [36] that is a downloadable command-line tool. 
It is also available on web a free graphical user interface called wANNOVAR [37]. 
wANNOVAR utilizes update information to annotate functionally genetic mutations, starting from a 
list of variants (vcf files) that contains chromosome localization, start position, end position, reference 
nucleotide and observed nucleotides. The reference genome used to annotate variants is hg19 
(GRChg37 genome assembly). 
The wANNOVAR output is a table that contains several information on gene-based annotation that 
identifies whether SNPs or CNVs is located in an exon or in an intron, the amino acids that are 
mutated and the aminoacids change. The exonic variants are classified as non-synonymous SNV, 
synonymous SNV, frameshift insertion, frameshift deletion or unknown when different isoforms are 
available, and it is not possible to assign single annotation. 
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For each variant identified, wANNOVAR classifies if is reported in specific databases (i.e. dbSNP, 
1000 Genome Project, NHLBI-ESP 6500 exomes, Exome Aggregation Consortium) and shows the 
frequency in different populations. When a dbSNP identifier (rs number) is available, wANNOVAR 
annotate it. wANNOVAR also reports the scores and the prediction for the aminoacids substitutions 
using different in silico predictor tools [38]. 
 
1.10 In silico predictor tools 
 
In silico predictor tools are useful to evaluate the pathogenicity of the variants, considering several 
parameters, such as phylogenetic data, protein structure, and they compute an indicative score of the 
probability of the variant to be disease-related.  
The most frequently used and reported by wAnnovar output are: 
- SIFT prediction is based on the degree of conservation of amino acid residues in sequence 
alignments derived from closely related sequences, collected through PSI-BLAST. The 
Scores range from 0 to 1; the smaller the score the more likely the SNP has damaging effect 
[39]. 
- PolyPhen-2 (Polymorphism Phenotyping v2) predicts the functional significance of an amino 
acid substitution by Naïve Bayes classifier, using sequence-based and structure-based 
predictive features. HDIV, or HumDiv, identifies human damaging mutations by assuming 
differences between human proteins and their closely related mammalian homologus as non-
damaging. HVAR, or HumVar, identifies human disease-causing mutations by assuming 
common human nsSNPs as non-damaging. The score ranges from 0 to 1 [40]. 
- MutationTaster evaluates the disease-causing potential of DNA sequence alterations by Naïve 
Bayes classifier, integrating information of evolutionary conservation, splice-site changes, 
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loss of protein features and changes that might affect the amount of mRNA from different 
biomedical databases and uses established analysis tools [41]. 
- Mutation Assessor predicts the functional impact of amino-acid substitutions in proteins based 
on evolutionary conservation of the affected amino acid in protein homologous. The 
score ranges from -5.545 to 5.975 in dbNSFP [42]. 
- LRT (likelihood ratio test) identifies conserved amino acid positions and deleterious 
mutations using a comparative genomics data set of multiple vertebrate species. The original 
LRT two-sided p-value (LRTori), ranges from 0 to 1 [43]. 
- FATHMM (Functional Analysis through Hidden Markov Models) predicts the functional 
consequences of cancer-associated amino acid substitutions using a model weighted for 
inherited disease mutations. Scores range from -16.13 to 10.64. The smaller the score the more 
likely the SNP has damaging effect [44]. 
- RadialSVM score is an ensemble-based approach integrating multiple scoring systems 
(function prediction and conservation Score) by radial support vector machine.  
- LR score is an ensemble-based approach integrating multiple scoring systems (function 
prediction and conservation Score) by logistic regression (LR).  
- CADD (Combined Annotation Dependent Depletion) score is a framework that integrates 
multiple annotations into one metric for functional prediction of a SNP. Scores range from   -
7.535037 to 35.788538 in dbNSFP; the larger the score the more likely the SNP has damaging 
effect. [45]. 
- phyloP calculate a conservation score based on the multiple alignments of 7 vertebrate 
genomes (including human). The larger the score, the more conserved the site. Scores range 
from -5.172 to 1.062 in dbNSFP [46]. 
- GERP++ calculates site-specific “rejected substitutions” (RS) scores and to discover 
evolutionarily constrained elements based on maximum likelihood evolutionary rate 
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estimation. Scores range from-12.3 to 6.17; the larger the score, the more conserved the site 
[47]. 
- SiPhy detects bases under selection from a multiple alignment data using a hidden Markov 
model. It evaluate the estimated stationary distribution of A, C, G and T at the site, using an 
algorithm based on 29 mammals genomes [48]. 
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2. AIMS OF THE PROJECT 
 
? Recruitment of a cohort of non-syndromic sensorineural hearing loss subjects negative for 
GJB2/GJB6 molecular test.  
 
? Identification of the most comprehensive collection of genes associated with non-syndromic 
hearing loss, in order to develop a targeted gene panel that could be the translational delivery 
of the project. 
 
? Identification and molecular characterization of pathogenic variants; characterization of the 
molecular pathology of selected genes.  
 
? Development of an in-house database of variants that could represent an epidemiologic map 
of the studied population. 
 
? Genotype-phenotype correlation and better stratification of the different phenotypes. 
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3. MATERIAL AND METHODS 
 
3.1 Patients recruitment and sample collection 
 
A cohort of 78 subjects (54 females and 24 males), mainly of Caucasian origin, with sensorineural 
hearing loss of variable age of onset and clinical course were recruited in collaboration with many 
centers of Medical Genetics and departments of Audiology and Otorhinolaryngology, prevalently 
located in North-East of Italy. 
Appropriate genetic counseling was offered to each enrolled subject, provided regular written 
informed consent for molecular genetic testing was obtained. The work was conducted according to 
the ethical standards as defined by the Helsinki Declaration and according to indications from the 
local institutional ethics committee for current molecular diagnosis. 
 
3.2 Clinical information and audiometry evaluation 
 
Family history and clinical information about the hearing loss of the subjects enrolled were collected 
in an ad hoc form, which reported age of onset (congenital, peri-lingual, post-lingual, unknown) and 
type of hearing loss (neurosensorial, conductive, mixed), as well as laterality (bilateral, symmetric, 
asymmetric, monolateral), progression (stable, progressive, fluctuating, unknown), severity (mild, 
moderate, severe, profound) and audiogram shape (flat, U-shaped cookie-bite, down-sloping, rising, 
unknown).  Presence or absence of vestibular dysfunction or auditory neuropathy was also 
investigated. The previously performed single-gene tests were recorded. 
Hearing thresholds for each individual were tested at frequencies from 250 to 8000 Hz (Grason-
Stadler GSI 61 audiometer) in a sound-attenuating room. The degree of hearing impairment was 
defined by the pure tone average (PTA) threshold levels at 0.5, 1, 2 and 4 kHz, and was classified as 
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mild (PTA 21-40 dB HL), moderate (PTA 41-70 dB HL), severe (PTA 71-95 dB HL) and profound 
(PTA > 95 dB HL) [10]. 
 
3.3 DNA extraction and molecular characterization of GJB2/GJB6 
 
Genomic DNA (gDNA) was extracted with Maxwell automatic extractor (PROMEGA), according to 
the manufacturer’s instructions from 400 µl of peripheral blood samples anti-coagulated with EDTA. 
gDNA was quantified with NanoVue™ Plus Spectrophotometer (GE healthcare). 
GJB2 gene (NCBI reference sequence RefSeqNM_004004) was amplified using AmpliTaq Gold® 
(ThermoFisher SCIENTIFIC) with primers listed in Table 3.1 and PCR-thermal-cycling conditions 
listed in Table 3.2 and Table 3.3.  
2 µl of Exonuclease I and 2 µl of Shrimp Alkaline Phosphatase (IllustraExoProStar GE Healthcare 
Life Sciences) were added to 10 µl of PCR reaction, to clean-up the PCR products before sequencing; 
the mixture was incubated at 37°C for 30’, followed by incubation at 80°C for 15’. 
The sequencing reaction was performed in a total volume of 10 µl, of which 1 µl of BigDye® 
Terminator v3.1, 1 µl of primer (3.2 µM), PCR products (3-10 ng) and RNase/DNase free water.  
The sequencing products were purified with IllustraAutoSeq G-50 columns (GE Healthcare) and then 
analyzed with ABI PRISM 3130 Genetic Analyzer capillary sequencer (ThermoFisher 
SCIENTIFIC). 
 
 
 
 
Table 3.1 GJB2 primer sequences for PCR amplification. Tm: melting temperature GC%: percentage of GC bases. 
 
Gene Name Sequence Length (bp) 
Tm 
(C°) GC% Ampliconsize exon 
GJB2 cx26_R30 CGTAACTTTCCCAGTCTCCGAGGGAAGAGG 30 70,9 56,7 348 bp 1 
GJB2 cx26_L31 GCCCAAGGACGTGTGTTGGTCCAGCCC 27 72,6 66,7 
GJB2 cx26_F1 CATTCGTCTTTTCCAGAGCA 20 55,3 55,3 770 bp 2 
GJB2 cx26_R2 CCTCATCCCTCTCATGCTGT 20 59,3 55 
33 
 
Step Temperature Time Cycle 
Initial denaturation 94° C 12’ - 
Denaturation 
Annealing 
Extension 
94° C 
70° C 
72° C 
20’’ 
20” 
30’’ 
3X -
1°C/cycle 
Denaturation 
Annealing 
Extension 
94° C 
68° C 
72° C 
30’’ 
30” 
30’’ 
33X 
Final extension 72° C 7’ - 
Cooling 10° C ∞ - 
 
Table 3.2 Thermal cycling conditions for exon 1 of GJB2. 
 
Step Temperature Time Cycle 
Initial denaturation 94° C 12’ - 
Denaturation 
Annealing 
Extension 
94° C 
62° C 
72° C 
20’’ 
20” 
30’’ 
3X -
1°C/cycle 
Denaturation 
Annealing 
Extension 
94° C 
60° C 
72° C 
30’’ 
30” 
30’’ 
35X 
Final extension 72° C 10’ - 
Cooling 10° C ∞ - 
 
Table 3.3 Thermal cycling conditions for exon 2 of GJB2. 
The two GJB6 deletions (GJB6-D13S1830 and GJB6-D13S1854) were analyzed in a single PCR 
assay previously reported [24]. PCR products were separated by electrophoresis in a 1.5% agarose 
gel in TAE 0.5X buffer, stained with GelRed™ 10,000X (Biotium). The PCR products were visually 
compared with two positive control-sample for the deletions. 
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3.4 Hearing loss targeted NGS panel 
 
The hearing loss targeted gene-panel was constructed with the aim of developing a molecular tool 
with a high diagnostic rate for non-syndromic hereditary hearing loss, specifically in the pediatric 
Caucasian population. 
The genes-selection was performed after an accurate review of the literature, after consulting the most 
comprehensive public databases, such as OMIM (https://www.omim.org/); hereditary hearing loss 
homepage (http://hereditaryhearingloss.org/); deafness variation database 
(http://deafnessvariationdatabase.org/) and after the evaluation of the targeted gene-panel already 
available in the market. 
The selection originally included about 100 genes, known to be hearing loss disease-genes or 
candidate genes; then the filtration process was performed, ending with a panel including 59 genes 
plus non-coding exon 1 of GJB2. 
The criteria used for genes inclusion were: i) only genes known to be mutated at least once in 
Caucasians; ii) genes related to non-syndromic hearing loss, except Pendred and Usher Syndrome 
genes, because the onset of hearing loss is earlier than other clinical manifestations. This means that 
these two disorders, at onset, may be clinically indistinguishable from isolated hearing loss, but 
absolutely need an early diagnosis to optimize clinical follow-up and rehabilitation strategies; iii) 
genes that were found to be mutated in humans and not only in experimental animal; iv) genes with 
proven pathogenic role. 
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3.5 Ion Torrent process overview 
 
3.5.1 Target selection 
 
Ion AmpliSeq Designer v.4.4.1 software (https://www.ampliseq.com) was used to select primers for 
preparation of DNA libraries. The designer required as input the reference genome, the gene-list, the 
region of interest (CDS only or CDS and UTR), the padding around exons (10 bp or 25 bp) and the 
amplicons-size range (125-225 bp or 125-375bp for standard DNA). 
GRCh37/hg19 was selected as reference genome to create the amplicons for the 59 genes; it was 
requested to consider the CDS and UTR with 10 bp of exon-padding. It was also manually added 
non-coding exon 1 of GJB2, by insert genomic coordinate. 
The system designed a total of 1,646 amplicons divided in two primer-pools of 827 and 819 amplicons 
respectively. The amplicon size-range was 125-375 bp, with a mean of 228 bp; the designed gene-
panel ensured overall targeted region coverage of 98.6% spanning through 456.8 Kb of sequence, 
with 3,153 bp missed. 
 
3.5.2 Library preparation 
 
gDNA was quantified with Qubit 2.0 Fluorometer using the Qubit® dsDNA High Sensitivity Assay 
Kit (ThermoFisher SCIENTIFIC). 
The DNA libraries were constructed starting from 10 ng of gDNA and each primer-pool was 
amplified in two separate reaction with Ion AmpliSeq DNA Library Kit 2.0 (ThermoFisher 
SCIENTIFIC), using the thermal cycling condition reported in Table 3.4.  
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Step Temperature Time Cycle 
Activate the enzyme 99° C 2’ - 
Denaturation 
Annealing and 
Extension 
99° C 
60° C 
15’’ 
4’ 15X 
Cooling 10° C ∞ - 
 
Table 3.4 Thermal cycling conditions for library amplification. 
After the target-amplification reaction, the tubes containing each amplified pool were combined 
together and the primer sequences were partially digested with 2 µl of FuPa Reagent using the 
conditions listed in Table 3.5. 
 
Temperature Time 
50° C 10’ 
55° C 10’ 
60° C 20’ 
10° C Hold (for up to 1 hour) 
 
Table 3.5 Thermal cycling conditions for FuPa reaction. 
The libraries were barcoded with Ion Xpress Barcode Adapters Kit, that were ligated to the amplicons 
with DNA ligase according to the manufacturer's instructions and with the thermal cycling condition 
listed in Table 3.6. 
 
Temperature Time 
22° C 30’ 
68° C 5’ 
72° C 5’ 
10° C Hold (for up to 1 hour) 
 
Table 3.6 Thermal cycling conditions for the ligation of the barcode. 
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The unamplified libraries were purified with Agencourt AMPure® XP purification system (Beckman 
Coulter), using a final concentration of 1.5X of beads to sample volume-ratio.150 μl of freshly 
prepared 70% ethanol was used two times to wash the beads that contained the desired libraries, 
which were then eluted and amplified with Platinum® PCR SuperMix High Fidelity and Library 
Amplification Primer Mix, with condition listed in Table 3.7. This step permitted to enrich 
amplifiable material and obtain sufficient library for accurate quantification. 
 
Temperature Time Cycle 
98° C 2’ - 
98° C 
64° C 
15’’ 
1’ 5X 
10° C ∞ - 
 
Table 3.7 Thermal cycling conditions for library amplification.  
The amplified libraries were purified with Agencourt AMPure® XP reagent using two rounds of 
purification: first round at 0.5X bead-to-sample-volume ratio to elute the amplicons and primers, and 
a second round at 1.2X bead-to-sample-volume ratio to bound the amplicons to the beads, that were 
then eluted with 50 µl of low TE. 
10 µl of purified libraries were analyzed with Qubit dsDNA HS Assay Kit and then was determined 
the dilution factor that results in a concentration of ~100 pM (or ~15-22 ng/mL). 
 
3.5.3 Template preparation 
 
Six libraries at 100 pM were combined in equal volume and then diluted to a final concentration of 
16 pM in a total volume of 25 µl.  
The diluted libraries were added to 800 μl of Ion PGM™ Hi-Q™ Reagent Mix, in which were also 
added 25 µl of Nuclease Free Water, 50 µl of Ion PGM™ Hi-Q™ Enzyme Mix and 100 µl of Ion 
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PGM™ Hi‑Q™ ISPs. The solution was loaded in the Ion OneTouch™ Reaction Filter with 1.7 ml 
of Ion OneTouch™ Reaction Oil. The prepared filter was loaded in the Ion PGM™ One Touch 2 
Instrument. 
After the run completed the template-positive Ion PGM™ Hi-Q™ ISPs (ThermoFisher SCIENTIFIC) 
were recovered according to the manufacturer’s protocol and then enriched with the Ion OneTouch™ 
ES instrument (ThermoFisher SCIENTIFIC) using Dynabeads® MyOne™ Streptavidin C1 Beads 
(ThermoFisher SCIENTIFIC). 
2 µl of unenriched template-positive Ion PGM™ Hi-Q™ ISPs were used to perform the quality 
control by adding 19 µl of Annealing Buffer and 1 µl of Ion Probes. The mix was incubated at 95°C 
for 2’ followed by 37°C for 2’. After three washing steps, the fluorescence of Alexa Fluor® 488 and 
Alexa Fluor® 647 was measured and then, using the Qubit® Easy Calculator Microsoft® Excel® 
Spreadsheet file, the percent of templated-ISPs was calculated; according to manufacturer’s 
instruction the optimal values range between 10-30%. 
 
3.5.4 Sequencing 
 
The Ion PGM machine (ThermoFisher SCIENTIFIC) was used to carry out the sequencing process. 
The instrument was firstly cleaned with 18 MΩ water and then with chlorite solution. After the 
cleaning procedure, the initialization process was performed according to the manufacturer’s 
instructions. The Ion PGM™ Hi-Q™ Sequencing Kit (ThermoFisher SCIENTIFIC) was used to 
prepare and sequence the enriched template positive ISP; in particular 5 μl of Control ISPs were 
added directly to the entire volume of ISPs, followed by a centrifugation step. 12 μl of Sequencing 
Primer were added to the 15 μl of ISP collected after centrifugation; the mix was incubated at 95°C 
for 2’ and then 37°C for 2’. After the incubation step, 3 μl of Ion PGM™ Hi‑Q™ Sequencing 
Polymerase were added to the ISPs. 
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The mixture was loaded into the Ion 316™ Chip v2 (ThermoFisher SCIENTIFIC) as recommended 
by the manufacturer. The prepared chip was then placed into PGM machine for sequencing. 850 flows 
of sequence were used for the 316 Chip, as suggested by the manufacturer’s protocol. 
The run was planned in the Torrent Suite Software, giving the information about the setting used in 
the sequencing, the number of flows, the kit type, the barcode, the run type, the reference file 
(genome) and the target region (BED file). 
 
3.5.5 Data analysis 
 
Sequencing data were stored in the Torrent Server and then processed by the Ion Torrent Suite™ 
Softwarev4.4 and later. Single Nucleotide Variants (SNV) and small insertion/deletions (INDELs), 
generated by the variant caller plug-in, were then annotated using the free web tool wANNOVAR 
(http://wannovar.wglab.org/) [37].  
The reads alignment was visualized using the Integrative Genome Viewer (IGV) software 
(http://software.broadinstitute.org/software/igv/).  
The variants were filtered based on: i) minor allele frequency (MAF) in healthy individuals (<1%) as 
reported in public database (dbSNP, 1000Genomes, ESP6500, ExAC, gnomAD) to exclude possible 
polymorphisms. ii) Depth coverage higher than 20X. iii) Localization of the variant (exonic, intronic, 
3’ UTR or 5’UTR). iv) Type of molecular alteration (frameshift variants, non-synonymous SNV, 
stop-gain mutation, splice-site mutations). 
The pathogenicity of missense mutation was evaluated with a cluster of  in silico predictor tools: SIFT 
[39], Polyphen-2 [40], MutationTaster [41], MutationAssessor [42], LRT [43], FATHMM [44], 
RadialSVM, LR, CADD_phred [45].  
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The alteration at protein level and the aminoacid conservation was evaluated with PhyloP [46] 
GERP++ [47], SiPhy [48], Proviz (http://proviz.ucd.ie/) [49]. Information on the structural domain 
involved and protein structures were obtained consulting UniProt (http://www.uniprot.org/). 
The prediction of splice-site mutations was performed with Human Splicing Finder 
(http://www.umd.be/HSF3/) [50].  
The disease-specific database and clinical-associated database as Deafness Variation Database 
(http://deafnessvariationdatabase.org/), ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) and The 
Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php) were also used to 
determine the pathogenic role of the variants. 
ACMG guidelines [51] and InterVar tool (http://wintervar.wglab.org/) [52] were used to classify the 
mutations, which were named according to HGVS recommended nomenclature [53]. 
. 
3.6 Sanger sequencing and family segregation analysis 
 
For diagnostic purposes, we decided to adopt a cut-off depth of coverage of 100 X.  
Likely pathogenic variants, either new or known in literature, with a depth of coverage of less than 
100 X, were systematically validated by conventional Sanger sequencing, using primers designed in-
house with Primer3Plus (https://primer3plus.com/) or designed by the AmpliSeq designer. The PCR 
reactions were performed using AmpliTaq Gold® (ThermoFisher SCIENTIFIC) with standard PCR-
thermal-cycling conditions, as reported by the manufacturer’s instructions. PCR products were 
purified using ExoSAP-ITTM (ThermoFisher SCIENTIFIC Waltham, MA USA) and sequencing 
reactions were performed with BigDye® Terminator v3.1 kit according to manufacturer’s instruction. 
The sequencing products were analyzed with 3130 Genetic Analyzer capillary sequencer 
(ThermoFisher SCIENTIFIC Waltham, MA USA).  
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Family segregation analysis was performed, whenever possible, to evaluate the de novo or inherited 
nature of the variant. 
 
3.7 RNA extraction and cDNA analysis 
 
PAXgene Blood RNA Tube was used, according to manufacturer’s instruction, to collect blood for 
subsequent RNA extraction, which was performed with the PAX gene Blood RNA Kit, as reported 
by the manufacturers’s protocol. Total RNA was quantified with NanoVue™ Plus Spectrophotometer 
(GE healthcare). 
100 ng of total RNA was reverse-transcribed using SuperScript II Reverse Transcriptase 
(ThermoFisher SCIENTIFIC) and random hexaprimers (Invitrogen), according to the manufacturer’s 
instructions. The RNA plus random hexaprimers was rapidly denatured at 65°C for 5’ and then quick 
chilled on ice. 5X First-Strand Buffer, 0.1 M DTT and RNAase OUT (40U/μl) were added to the 
mixture which was incubated at 25° for 2’, before adding SuperScript II RT (200 units). 
The RT-PCR protocol was carried out as follows: 25°C for 10’, 42°C for 50’ and 70°C for 15’. 
2μl of the obtained cDNA were used to amplify exons 59, 60, 61 of CDH23 gene, to evaluate the 
molecular effect of the novel splice-site mutation identified by NGS.  
The PCR was performed with AmpliTaq Gold® (ThermoFisher SCIENTIFIC) with two different 
primers–pair, listed in Table 3.8, that amplify simultaneously the three exons. The PCR-thermal-
cycling conditions are listed in Table 3.9. 
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Table 3.8 CDH23 primer sequences for PCR amplification. Tm: melting temperature GC%: percentage of GC bases. 
 
Step Temperature Time Cycle 
Initial denaturation 94° C 2’ - 
Denaturation 
Annealing 
Extension 
95° C 
58° C 
72° C 
45’’ 
45” 
45’’ 
40X 
Final extension 72° C 7’ - 
Cooling 10° C ∞ - 
 
Table 3.9 Thermal cycling conditions for amplification of exons 59, 60 and 61 of CDH23 gene. 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Name Sequence Length (bp) Tm (C°) GC% 
Amplicon 
size exon 
CDH23 CDH23_ex59_a_F CGGCAACGAAGAGAAGAACT 20 59,6 50 455bp 59,60,61 
CHD23 CDH23_ex61_a_F CCATGAAGAGGTCGAAGGTG 20 60,6 55 
CDH23 CDH23_ex59_b_F TTGTGCTAGAGGACATCAACG 21 58,9 47,6 445bp 59,60,61 CDH23 CDH23_ex61_b_F ATGTTGGAGAGCAGGTGGAT 20 59,5 50 
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4. RESULTS 
 
4.1 Cohort of recruited subjects 
 
A total of 130 blood samples from subjects with apparent non-syndromic hearing loss clinically 
ascertained and clinically characterized by many Medical Genetics Centers and departments of 
Audiology and Otorhinolaryngology mainly located in the North-East of Italy were collected.  
All the selected individuals had previously been tested for GJB2 mutations/GJB6 deletions, and 
resulted negative. 
A subset of 78 selected individuals have so far been tested with our customized NGS targeted panel 
approach. The analyzed cohort includes 54 females and 24 males, with ages ranging from 1 to 68-
years: average age 20-years (SD ± 18.5); mode 7-years and median age 13-years.  
In particular the cohort was stratified as follow: 14 children with ages from 0-5 years old; 18 subjects 
with ages from 6-10 years old; 16 individuals with ages from 11-15 years old; 4 subjects with ages 
from 16-20 years old; 6 individuals with ages from 21-30 years old; 5 subjects with ages from 31-40 
years old; 8 subjects with ages from 41-50 years old; 8 subjects with ages from 51-60 years old and 
4 individuals with more than 60 years.  
In the selected cohort, the age of onset of the hearing loss was as follows: 38 cases with documented 
congenital hearing loss, 7 with peri-lingual HL, 23 with post-lingual and 10 with unspecified onset 
of the hearing deficit. Among the 78 subjects tested, 4 individuals with bilateral and asymmetric HL 
were included, all the other had bilateral symmetric HL. 
The course of the HL was prevalently stable (42/78 subjects), while it was progressive in 22/78; in 
only 1 individual HL was fluctuating and the course of the defect was unknown in 13 individuals.  
In 28 of the tested subjects the degree of HL was profound, it was severe in 23, moderate in 20 and 
mild in only 4 individuals. 
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4.2 Targeted gene panel 
 
4.2.1 Results of gene-selection 
 
The targeted gene-panel, developed to analyze mainly genes responsible for non-syndromic deafness 
or hearing loss with non-syndromic onset in Caucasian, was obtained after an accurate gene-selection 
process, explained in detail in section 3.4. The final targeted gene-panel comprised 59 genes, listed 
in Table 4.1. The targeted gene-panel included 26 autosomal recessive (AR) genes, 17 autosomal 
dominant (AD) genes, 4 X-linked genes, 11 Usher syndrome genes (inherited as autosomal recessive) 
and the auditory neuropathy gene (inherited as autosomal dominant).  
 
 
Autosomal recessive 
genes (n=26) 
CLDN14; COL11A2; DFNB59; ESPN; GIPC3; GJB2; GJB3; GJB6; GRXCR1; HGF; 
MYO15A; MYO6; OTOA; OTOF; OTOG; OTOGL; PTPRQ; RDX; SLC26A4; 
SLC26A5; STRC; TBC1D24; TECTA; TMC1; TMPRSS3; TPRN 
Usher syndrome 
genes (n=11) 
CDH23; CIB2; CLRN1; GPR98; MYO7A; PCDH15; PDZD7; USH1C; USH1G; 
USH2A; WHRN 
Autosomal dominant 
genes (n=17) 
ACTG1; CCDC50; CEACAM16; COCH; DFNA5; EYA4; GRHL2; HOMER2; KCNQ4; 
LEDGF; MIR96; MYH14; MYH9; OSBPL2; P2RX2; POU4F3; SLC17A8 
Auditory neuropathy 
gene (n=1) 
DIAPH3 
X-linkedgenes         
(n=4) 
COL4A6; POU3F4; PRPS1; SMPX 
 
Table 4.1 Genes included in the targeted-gene panel. 
 
4.1.1 Ampliseq designer results 
 
The Ampliseq designer v.4.4.1 designed for the selected-genes, a total of 1,646 amplicons divided in 
two primers pools. The total covered bases were 226.8 Kb that ensured overall targeted region 
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coverage of 98.6%. The missed bases (3,153 bp) were located in particular in exon 1 or in GC-rich 
regions. 
In particular there were 36 genes covered at 100%, 13 genes had a coverage ranging between 97 and 
99%, 8 genes were covered ranging between 90 and 95% and 2 genes (ESPN, P2RX2) were covered 
less than 85%, as reported in Table 4.2. 
 
gene name # exons  # amplicons total bp covered bp missed bp overall coverage % 
ACTG1 5 7 1,228 1,169 59 95.2 
CCDC50 12 16 1,689 1,689 0 100 
CDH23 73 91 11,849 11,702 147 98.8 
CEACAM16 6 10 1,398 1,398 0 100 
CIB2 7 7 684 650 34 95 
CLDN14 1 4 740 740 0 100 
CLRN1 9 8 1,051 1,051 0 100 
COCH 11 14 1,873 1,873 0 100 
COL11A2 67 63 6,606 6,572 34 99.5 
COL4A6 47 49 6,078 6,078 0 100 
DFNA5 10 11 1,671 1,671 0 100 
DFNB59 6 8 1,179 1,179 0 100 
DIAPH3 31 34 4,290 4,290 0 100 
ESPN 13 18 2,825 2,339 486 82.8 
EYA4 20 20 2,421 2,421 0 100 
GIPC3 6 7 1,059 1,055 4 99.6 
GJB2 1 4 701 701 0 100 
GJB3 1 4 833 833 0 100 
GJB6 1 3 806 806 0 100 
GPR98 90 128 20,721 20,707 14 99.9 
GRHL2 16 19 2,198 2,198 0 100 
GRXCR1 4 6 953 953 0 100 
HGF 21 20 2,583 2,562 21 99.2 
HOMER2 10 10 1,245 1,220 25 98 
KCNQ4 14 18 2,368 2,326 42 98.2 
LEDGF 16 17 1938 1920 18 99,1 
MIR96 1 2 97 97 0 100 
MYH14 42 50 6,951 6,951 0 100 
MYH9 40 50 6,683 6,683 0 100 
MYO15A 64 84 11,873 11,146 727 93.9 
MYO6 34 39 4,538 4,538 0 100 
MYO7A 51 65 7,642 7,642 0 100 
OSBPL2 16 13 1,773 1,773 0 100 
OTOA 30 31 4,058 4,056 2 99 
OTOF 50 60 7,259 6,964 295 95.9 
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OTOG 55 73 9,878 9,624 254 97.4 
OTOGL 58 65 8,195 8,195 0 100 
P2RX2 19 12 1,718 1,448 270 84.3 
PCDH15 43 52 8,284 8,284 0 100 
PDZD7 17 22 3,474 3,422 52 98.5 
POU3F4 1 6 1,106 1,106 0 100 
POU4F3 2 6 1,057 1,057 0 100 
PRPS1 8 8 1,097 1,097 0 100 
PTPRQ 42 54 7,224 7,224 0 100 
RDX 19 18 2,099 2,099 0 100 
SLC17A8 12 14 2,010 2,010 0 100 
SLC26A4 20 21 2,743 2,743 0 100 
SLC26A5 20 19 2,652 2,652 0 100 
SMPX 3 3 327 327 0 100 
STRC 29 37 5,908 5,897 11 99.8 
TBC1D24 7 14 1,820 1,820 0 100 
TECTA 23 35 6,928 6,928 0 100 
TMC1 20 21 2,683 2,654 29 98.9 
TMPRSS3 15 12 1,688 1,688 0 100 
TPRN 4 12 2,216 2,088 128 94.2 
USH1C 29 33 3,334 3,100 234 93 
USH1G 4 8 1,446 1,302 144 90 
USH2A 72 92 17,043 17,043 0 100 
WHRN 14 18 2,964 2,841 123 95.9 
 
Table 4.2 Results obtained from Ampliseq Designer v.4.4.1. Number (#) of exons, number (#) of amplicon; total base pair 
(bp), covered bp, missed bp and overall coverage expressed as percentage for the selected genes. 
 
4.2 Coverage analysis plug-in results 
 
The summary of the average values output of Ion Torrent Coverage analysis plug-in is reported in 
Table 4.3. In particular, for each individual an average of 522,405.12 reads were mapped, of which 
94.37% were on-target. For each amplicon, an average of 295.55 reads were aligned. The average 
base coverage obtained was 249.03X and 91.11% of target bases were covered at least 20X, while 
68.45% bases were covered 100X.  
The mean amplicon length was 236.46 bp, as expected from the AmpliSeq design, which calculate a 
mean amplicon length of 228 bp. 
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Table 4.3 Mean value and standard deviation (SD) of the data obtained from Ion Torrent coverage analysis plug-in. 
 
4.3 Variant caller plug-in results 
 
The variant Caller plug-in produced an average of 499 (SD ± 47) variants (SNVs and INDELs) per 
individual, of which 131 (SD ± 47) were exonic and 368 (SD ± 41) were intronic. 
According to the criteria explained in detail in section 3.5.6, the final number of candidate variants 
was reduced to a mean of 9 variants per subjects (SD ± 4.3). 
Some of the filtered variants resulted to be common alignment errors and were further excluded. 
A total of 1,311 unique variants, present in only one individual of the analyzed cohort, were identified; 
among which, 871 were covered higher than 20X. 448 of the filtered variants had an rs accession 
number reported in dbSNP and only 8 were reported in ClinVar database as pathogenic or likely 
pathogenic. 
Over the 871 variants there were 297 exonic (162 non-synonymous SNV, 92 synonymous SNV, 13 
frameshift deletions, 10 frameshift insertions, 7 non-frameshift deletions, 2 non-frameshift insertions, 
3 non-frameshift substitutions, 4 stop-gain, 4 unknown) and 574 intronic (5 splice-site mutation, 5 
localized at 5’UTR and 18 localized at 3’UTR). The “unknown” called variants were further manually 
annotated considering the main isoform of the gene. 
48 
 
After an accurate evaluation and filtration process, 43 variants were reported as pathogenic, from 
which 18 were novel (41.8%), never described in literature, nor present in the public databases of 
healthy population or disease-specific. All the likely pathogenic variants identified are reported in 
Table 4.4, while the list of novel mutations with in silico prediction of pathogenicity is reported in 
Table 4.5. 
The most frequently mutated gene in the analysed cohort was CDH23, with 13 likely causative 
variants, of which 4 were never previously described, as reported in Figure 4.1. The three GJB2 
mutations identified in two samples were previously missed with the Sanger sequencing analysis. 
 
 
Figure 4.1 Histogram of the frequently mutated genes. X-axis reports the genes with likely causative variants. Y-axis 
represents the number of mutations. Blue bar indicates the total identified mutations, orange bars represents the novel 
one. 
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ID # Sex Ag e G ene Ref .  Seq Nucl eoti de Am i noa ci d rs  dbSNP Nucl eoti de Am i noa ci d rs  dbSNP Inheri tance
91 m 4 ACTG1 NM_001614 c.499G>A p.Glu167Lys // // // // AD
125 f 4 ADGRV1 NM_032119 c.2127_2137del p.Pro709fs //  c.10084C>T p.Gln3362Stop // AR *
10 m 11 CDH23 NM_022124 c.893T>C                     p.Leu298Pro // c.924_926del                     p.309delPro // AR
118 f 1 CDH23 NM_022124 c.2263C>T p.His755Tyr rs181255269 c.2263C>T p.His755Tyr rs181255269 AR *
151 f 13 CDH23 NM_022124 c.3293A>G p.Asn1098Ser rs41281310  c.1096G>A  p.Ala366Thr rs143282422 AR *
160 f 53 CDH23 NM_022124 c.7558G>A p.Glu2520Lys // c.7558G>A p.Glu2520Lys // AR *
8 f 16 CDH23 NM_022124 c.6530C>A p.Pro2177His rs748946014 c.8966-1G>C // // AR
34 m 3 CDH23 NM_022124 c.2304+1G>A // rs41281316 c.6050-9G>A // rs367928692 AR Usher syndrome
77 f 8 CDH23 NM_022124 c.7558G>A p.Glu2520Lys  //                      c.1515-12G>A //    rs3693967013                      AR
81 f 18 CDH23 NM_022124 c.4625G>A p.Gly1542Asp   rs781339262  c.7361C>T p.Thr2454Met        rs772949926 AR
141 m 30 CEACAM16 NM_001039213 c.1124C>A p.Ala375Gln // // // // AD
9 f 13 COCH NM_004086 c.1348A>G p.Ile450Val rs139503327 // // AD
23 f 41 COCH NM_004086 c.1271A>G p.Tyr424Cys // // // // AD
122 m 15 COCH NM_004086 c.320A>G p.Asn107Ser // // // // AD
147 f 47 COL11A2 NM_080681 c.998C>A p.Pro333Gln // // // // AD
14 f 9 EYA4 NM_004100 c.1154C>T p.Ser385Leu // // // // AD
38 f 14 EYA4 NM_004100 c.925A>G p.Thr309Ala rs556335059 // // // AD
76 f 7 GJB2 NM_004004 c.71G>A p.Trp24Stop rs104894306 c.71G>A p.Trp24Stop rs104894306 AR
56 m 9 GJB2        NM_004004 c.101T>C                            p.Met34Thr                           rs35887622                c.35delG                          p.Gly12fs                       rs80338939 AR
11 f 30 GJB3 NM_024009 c.659A>T p.Lys220Met // // // // AD
138 m 10 KCNQ4 NM_172163 c.1723C>T p.Arg575Trp // // // // AD
153 f 7 MYH9 NM_002473 c.3485+6C>T // rs867754177 // // // AD
114 m 6 MYO6 NM_004999 c.3554C>G p.Pro2285Arg rs762361071 // // // AD
99 f 1 MYO7A NM_000260 c.4921G>A p.Glu1641Lys rs767975012 // // // AD
5 f 12 MYO7A     NM_000260 c.730C>T             p.Arg244Cys              rs373942326 c.1117C>T             Arg373Cys               // AR
68 f 15 OTOG NM_001292063 c.6713G>A p.Gly2238asp rs528937385 c.7693+1G>A // rs548496846 AR
51 f 47 PTPRQ NM_00145026 c.4871-1G>C // // c.4871-1G>C // // AR
132 m 33 SLC17A8 NM_139319 c.861A>G p.Ile287Met rs770205149 // // // AD
86 f 1 SLC17A8  NM_139319 c.549_555del                                     p.Gly183fs                    //                        // // // AD
15 f 32 SLC26A4 NM_000441 c.1001+1G>A // rs80338849 // // // AR
109 f 65 SLC26A4 NM_000441  c.1001+1G>A    //        rs80338849                      // // // AR
120 m 10 STRC NM_153700 c.4917_4918delACinsCT // rs727503441 c.4917_4918delACinsCT // rs727503441 AR *
3 m 26 TMC1 NM_138691 c.2230C>T p.Arg744Stop rs150738413 // // rs150738413 AD
83 f 7 TMPRSS3 NM_02422 c.1224delA p.Gln408fs //  c.446+1G>T // // AR *
Allele #1 Allele #2
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InterVar automated InterVar adjusted
ACTG1 NM_001614 c.499G>A p.Glu167Lys D P B D D H D D D 15.25 3.63 7.446 11.342 uncertain significance likely pathogenic
ADGRV1 NM_032119 c.2127_2137delp.Pro709fs // // // // // // // // // 35* // // // // //
ADGRV1 NM_032119  c.10084C>T p.Gln3362Stop // // // N A // // // // 42 3.02 1.102 13.95 // //
CDH23 NM_022124 c.893T>C                     p.Leu298Pro D D D D D M T D T 16.8 4.22 7.431 13.457 uncertain significance uncertain significance
CDH23 NM_022124 c.924_926del                     p.309delPro // // // // // // // // // 21.3* // // // // //
CDH23 NM_022124 c.7558G>A p.Glu2520Lys D D D D D H T D D 22.7 4.99 9.289 18.624 uncertain significance NA
CEACAM16 NM_001039213 c.1124C>A p.Ala375Gln D D D // D L T T T 21.5 5.87 2.609 15.779 uncertain significance likely pathogenic
COCH NM_004086 c.1271A>G p.Tyr424Cys D D D D D M D D D 17.66 6.02 7.470 16.549 uncertain significance likely pathogenic
COCH NM_004086 c.320A>G p.Asn107Ser T D P D D M D D D 25.5 5.96 7.619 14.678 likely pathogenic likely pathogenic
COL11A2 NM_080681 c.998C>A p.Pro333Gln T D D D D L D D D 22.5 4.41 3.710 12.690 uncertain significance NA
EYA4 NM_004100 c.1154C>T p.Ser385Leu D D D D M D D D D 35 5.56 7.818 19.512 uncertain significance likely pathogenic
GJB3 NM_024009 c.659A>T p.Lys220Met T D D D D L D D D 22.5 4.41 3.71 12.69 uncertain significance uncertain significance
KCNQ4 NM_172163 c.1723C>T p.Arg575Trp D D D D D M D D D 18.84 1.4 0.268 12.163 uncertain significance uncertain significance
MYO7A     NM_000260 c.1117C>T             Arg373Cys               D D D // D M D D D 24.9 5.11 3.987 18.531 uncertain significance likely pathogenic
PTPRQ NM_00145026 c.4871-1G>C // // // // // D // // // // 12.62 5.59 7.904 19.595 // //
SLC17A8  NM_139319 c.549_555del                                     p.Gly183fs                   // // // // // // // // // 35* // // // // //
TMPRSS3 NM_02422 c.446+1G>T // // // // // D // // // // 17.12 4.94 6.023 18.165 // //
TMPRSS3 NM_02422 c.1224delA p.Gln408fs // // // // // // // // // 24.3* // // // // //
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4.4 Genotype - phenotype correlation 
 
The NGS analysis resulted negative in 13/78 subjects (16.7%), in which no pathogenic or likely 
pathogenic variants were found. We defined as “non-conclusive” 21/78 subjects (26.9%). Among the 
latter group, 14/21 subjects (66.7%) carried a monoallelic variant in a gene reportedly responsible of 
a recessive form of hearing loss; in 2/21 of the “non-conclusive” subjects (9.5%) two variants of the 
same gene were found and determined, by segregation analysis, to be in cis, while in 5/21 (23.8%) 
despite a pathogenic prediction, the identified variants did not seem to segregate with the deafness 
phenotype in the family. 
In 10/78 (12.8%) cases in which the possible prediction of pathogenicity for the identified mutations 
was not so strong, the highly recommended family segregation analysis is still pending.  
34 out of 78 studied subjects carried either a single pathogenic variant in a gene associated with a 
dominantly transmitted hearing loss or two pathogenic variants in a gene with autosomal recessive 
inheritance and so were classified as positive cases. Our analysis therefore resulted to have a 
diagnostic yield of 43.6%.   
The family history and audiological information on all the 34 positive-cases are reported in Table 4.6, 
while a graphical representation is reported in Figure 4.2.  
In particular, 20 of them had a positive family history of hearing loss, and in the vast majority (29/34) 
no consanguinity was reported in the family. The hearing loss was bilateral and symmetric in 31 
subjects, while it was bilateral and asymmetric in 3 subjects. 
The HL was predominantly congenital (14/34) or post-verbal (12/34). Stable HL was reported in 17 
of these subjects, while progressive in 10 cases. In only one subject a fluctuating course was 
documented. The HL was predominantly profound (12/34), then moderate (9/34), and severe (8/34); 
in only 2 cases it was reported as mild. 
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Figure 4.2 Familiar and audiological information of the NGS positive cases. X-axis reports the condition; Y-axis indicates 
the number (#) of subjects. 
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Table 4.6 Genotype-phenotype correlation of the positive cases. ID # indicates the identification number for each subject. 
M: male; F: female. dx: right sx: left. 
 
ID # Sex Age Gene famil iarity c onsanguineity onset lateral ity progression severity audiogram shape
91 m 4 ACTG1 no no congenital asymmetric stable moderate dx             severe sx unknown
125 f 4 ADGRV1 no no congenital bilateral stable moderate flat
10 m 11 CDH23 no no post-lingual bilateral progressive moderate U-shaped
118 f 1 CDH23 yes no congenital bilateral stable severe down-sloping
151 f 13 CDH23 no no post-lingual bilateral unknown mild flat
160 f 53 CDH23 yes yes post-lingual bilateral fluctuating profound unknown
8 f 16 CDH23 yes no peri-lingual bilateral stable profound unknown
34 m 3 CDH23 no no congenital bilateral stable profound unknown
77 f 8 CDH23 no no unknown bilateral progressive profound flat
81 f 18 CDH23 yes no post-lingual asymmetric progressive mild dx                      anacusia sx unknown
141 m 30 CEACAM16 yes no congenital bilateral unknown profound unknown
9 f 13 COCH yes no congenital bilateral stable profound unknown
23 f 41 COCH yes no post-lingual bilateral unknown severe down-sloping
122 m 15 COCH yes no peri-lingual bilateral stable moderate flat
147 f 47 COL11A2 yes no post-lingual bilateral progressive moderate flat
14 f 9 EYA4 yes no post-lingual bilateral progressive profound unknown
38 f 14 EYA4 no no unknown bilateral unknown moderate unknown
76 f 7 GJB2 yes yes congenital bilateral stable severe down-sloping
56 m 9 GJB2        yes yes peri-lingual bilateral stable moderate U-shaped
11 f 30 GJB3 yes no peri-lingual bilateral progressive severe down-sloping
138 m 10 KCNQ4 yes no post-lingual bilateral stable moderate U-shaped
153 f 7 MYH9 no no unknown bilateral progressive severe down-sloping
114 m 6 MYO6 no no congenital bilateral stable severe flat
99 f 1 MYO7A no yes congenital bilateral unknown severe down-sloping
5 f 12 MYO7A     no no post-lingual bilateral stable moderate flat
68 f 15 OTOG yes no post-lingual bilateral progressive moderate down-sloping
51 f 47 PTPRQ yes yes post-lingual bilateral progressive profound unknown
132 m 33 SLC17A8 yes no congenital bilateral stable profound flat
86 f 1 SLC17A8  no no congenital bilateral stable severe unknown
15 f 32 SLC26A4 yes no congenital bilateral unknown profound unknown
109 f 65 SLC26A4 yes no congenital bilateral progressive profound flat
120 m 10 STRC no no unknown bilateral stable mild down-sloping
3 m 26 TMC1 yes no congenital bilateral stable profound unknown
83 f 7 TMPRSS3 no no post-lingual asymmetric stable profound dx severe sx ski-slope
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4.5 Case reports 
 
4.5.1 Case 1: a case of consistent genotype-phenotype correlation 
 
The DNA sample of a Caucasian 47-year-old woman (II-1), heterozygote for a maternally transmitted 
GJB2 c.35delG mutation, was analyzed with the targeted gene panel. She presented bilateral 
sensorineural profound post-lingual hearing loss, with vestibular dysfunctions and referred onset at 
10 years of age. Her parents were consanguineous as illustrated in Figure 4.3 and both had congenital 
sensorineural hearing loss; the father also had vestibular dysfunctions. The two sisters of the proband 
were normal hearing. 
 
 
Figure 4.3 Family pedigree. The arrow indicates the proband (II-1). Square indicates males and circle female individuals. 
Solid symbol represents hearing-impaired individuals. +/- Heterozygous; +/+ homozygous; -/- wild-type 
 
A total of 524 variants were obtained for the proband, of which 389 intronic and 135 exonic. After 
the filtration process, a novel homozygous splice-site mutation in the PTPRQ gene (NM_001145026) 
was identified. The mutation, c.5390-1G>C, had never been described in literature or reported in 
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public databases. According to the Human Splicing Finder tool, this is an alteration of the exonic 
splicing silencer (ESS) site. This mutation, which had a total coverage of 88X, was visualized with 
IGV; and Sanger validated, as illustrated in Figure 4.4.  
 
 
 
Figure 4.4 A) IGV visualization of the reads. B) Electropherogram of the intron 31/exon 32 of the PTPRQ gene. The 
arrow indicates the c.5390-1G>C splice site mutation. C) Schematic representation of the splice-site variant location. 
Green circle represents the fibronectin type III domains. PTP: protein-tyrosin phosphatase 
 
The protein-tyrosine phosphatase, receptor-type, Q (PTPRQ) had both protein-tyrosine phosphatase 
activity and phosphatidylinositol phosphatase activity; it is associated with autosomal recessive non-
syndromic sensorineural hearing loss with vestibular dysfunction (DFNB84A; OMIM # 613391) 
[54]. The parents of the proband were both found to be heterozygote for of the splice site mutation. 
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4.5.2 Case 2: Early diagnosis of Usher Syndrome 
A 3-year-old Caucasian boy (II-1), born from non-consanguineous normal-hearing parents, as 
illustrated in Figure 4.5, was referred to our center because of congenital sensorineural bilateral 
profound hearing loss and peripheral retinal alteration. 
 
 
Figure 4.5 Family pedigree. The arrow indicates the proband (II-1). Square indicates males and circle female individuals. 
Solid symbol represents hearing-impaired individual. Half-coloured symbols indicate normal hearing subjects, carrier 
of the mutation. 
 
The targeted gene panel approach allowed the identification of 476 variants, of which 127 exonic and 
349 intronic; the filtration process pointed out two heterozygous likely pathogenic alterations in the 
CDH23 gene (NM_022124) c.2304+1G>A and c.6050-9G>A. 
The c.2304+1 G>A splice-site mutation, was localized in intron 22 and reported in dbSNP as 
rs769433759; it was not listed in the 1000 Genomes database but was reported in the disease-specific 
database (Deafness Variation Database and LOVD) as pathogenic and associated with Usher 
syndrome type 1D, based on published literature. This variant, previously known as IVS20+1G>A 
had originally been identified in a Dutch family with atypical Usher syndrome type I and in an 
European and a Spanish family with Usher syndrome type 1 [55]. 
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The pathogenic role of this variant was tested  in vitro by minigene assay which demonstrated this 
alteration to generate two different transcripts, one of which did not recognize the main splice donor 
site and created a new donor site including the first149 nucleotides of intron 21; the second transcript 
produced the skipping of exon 21 [56]. 
The second CDH23 variant identified, c.6050-9G>A, was localized in intron 46 and reported in 
dbSNP as rs367928692; it was reported in public databases with a very low frequency (4,969x10-5 
gnomAD browser, last accessed October 2017). This mutation, previously indicated as IVS45-9G>A, 
was reported in disease-specific databases as pathogenic and associated with Usher syndrome type 
1D. The two identified variants with a coverage of 74X and 82X respectively, were Sanger validated 
and evaluated with IGV, as illustrated in Figure 4.6 
 
 
Figure 4.6 A) IGV visualization of the reads with the variants. B) Schematic representation of splice-site variants position within the 
CDH23 gene. TM: transmembrane domain. 
 
The CDH23 gene encodes a member of the cadherin superfamily, which comprises calcium-
dependent cell-cell adhesion glycoproteins. The gene is associated both with autosomal recessive 
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non-syndromic hearing loss (DFNB12; OMIM # 601386) and with Usher syndrome type 1D (OMIM 
# 601067). It is reported in literature that CDH23 missense mutations tend to produce a less severe 
phenotype, both in Usher syndrome type I and in NSHL, whereas nonsense, splice-site, and frameshift 
mutations produce a severe Usher syndrome type I phenotype [57].  
Two splice-site mutations were identified in the child tested; as expected these were inherited from 
his unaffected parents, who were both carriers, as illustrated in Figure 4.5. According to the data 
reported in literature, this genotype could be associated with a severe Usher syndrome.  
 
4.5.3 Case 3: detection of a novel splice-site mutation and in vitro demonstration of its 
pathogenicity 
 
The proband (II-2), an 11-year-old Caucasian girl, presented sensorineural seemingly non-syndromic 
peri-lingual bilateral HL; the same phenotype was present in her 16-year-old sister, while the parents 
were normal hearing, as illustrated in Figure 4.7. 
 
 
Figure 4.7 Family pedigree. The arrow indicates the proband (II-2). Square indicates males and circle females 
individuals. Solid symbol represents hearing-impaired individuals. Half-coloured symbols indicate normal hearing 
subjects, carrier of the mutation.  
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The targeted gene panel approach allowed the identification of 457 variants in total, divided in 107 
exonic and 350 intronic variants; among which, the likely causative variants: c.6530C>A 
(p.Pro2177His) and c.8966-1G>C were located in the CDH23 gene (NM_022124). In Figure 4.8 is 
reported the IGV visualization of the reads and the positions of the gene variants. 
 
 
 
Figure 4.8 A) IGV visualization of the reads with the variants. B) Schematic representation of non-synonymous and splice-
site variants within the CDH23 gene. TM: transmembrane domain. 
 
The non-synonymous SNV c.6530C>A (p.Pro2177His), located in exon 48, was covered 209 X and 
was reported in dbSNP with rs748946014. It was identified in the general population with a low 
frequency (4.067x10-6 gnomAD browser, last accessed October 2017) and the aminoacid change was 
predicted deleterious by 8/9 in silico predictor tools, described in detail in section 1.10 and reported 
in Table 4.7. The Pro2177 residue was located in a highly phylogenetic conserved region (GERP++: 
5.28; CADD_Phred: 22) in a cadherin-domain of the protein, as shown in Figure 4.9. InterVar tool 
automatically predicted this mutation as of “unknown significance”. 
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Table 4.7 Results of in silico predictor tools. D: deleterious. H: high. // no prediction 
 
Figure 4.9 Multiple alignments of the CHD23 protein aminoacid sequence among species. Pro2177 is squared in red. 
 
The other identified variant, c.8966-1G>C, covered 566X was a novel splice-site mutation, not 
present in public databases, nor in disease specific databases. It was located in intron 59 and was 
predicted by human splicing finder tool to alter an intronic ESS site. The alterations seemed to 
determine a deletion of 90 bp in exon 60. 
Family segregation analysis was performed and demonstrated that the father carried the non-
synonymous SNV, the mother carried the splice-site mutation, while the sisters had both mutations. 
Considering this information on family segregation, InterVar parameters for the non-synonymous 
variant were manually adjusted and the missense variant could be classified as “likely pathogenic”. 
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To investigate on the specific effect of the novel splice site mutation, mRNA from the two affected 
sisters and the parents was retrotranscribed as described in section 3.7. The cDNA was amplified with 
specific primers, and the products were Sanger sequenced. As illustrated in Figure 4.10 the cDNA 
from the father, defined as wild-type, presented the entire sequences of the exons 59, 60, 61; while 
the cDNA of the sisters and of the mother showed skipping of the entire exon 60. 
 
 
Figure 4.10 Schematic representation of the splice-site position. Red arrows represent the primers used. Prediction of 
ESE finder tool and results of cDNA analysis. On the right, the electropherogram of wild-type and mutant cDNA. 
 
In this case, the targeted gene panel lead to the identification in the affected relatives of two variants 
that could be assigned to the pathogenic category. The exact pathogenic effect of the novel splice-site 
mutation was demonstrated in vitro. 
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4.5.4 Case 4: Dual molecular diagnosis in a family in which segregate non-syndromic 
HL and Waardenburg syndrome type 1 
 
The proband, a 9-year-old Caucasian girl (III-1) was referred to our department for an etiological 
evaluation of her sensorineural hearing loss. Her family history was positive for deafness as reported 
in Figure 4.11, with both congenital and post-lingual cases reported. No cardiac problems were 
present in the family. 
 
 
Figure 4.11 Family pedigree. The arrow indicates the proband (III-1). Square indicates males and circle female 
individuals. Solid symbol represents hearing-impaired individuals. +/- Heterozygous; +/+ homozygous; -/- wild-type. 
 
Pure tone audiometry revealed mild hearing loss, which was reported and documented as being post-
lingual. GJB2 analysis on the proband’s gDNA revealed the presence of a heterozygous c.35delG 
mutation, transmitted from her congenitally deaf homozygote mother (II-1), while the father tested 
negative.  
NGS analysis with the 59-targeted gene-panel was performed on the gDNA of the proband. The 
bioinformatics analysis finally highlighted a novel heterozygous mutation in exon 13 of the EYA4 
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gene: NM_004100.4: c.1154C>T (NP_004091.3: p.Ser385Leu). This variant wasn’t present in ExAC 
database (http://exac.broadinstitute.org/; last accessed September 2017) or in gnomAD browser 
(http://gnomad.broadinstitute.org/; last accessed September 2017). It was never described as 
associated with hearing phenotype nor it was present in deafness variation database 
(http://deafnessvariationdatabase.org; last accessed September 2017).  
All the utilized in silico tools, predicted this alteration as damaging since substituting a polar 
aminoacid with a non-polar one in a highly phylogenetically conserved residue (CADD phred: 35) 
within the functionally relevant eya-homologous region (eyaHR) as reported in Figure 4.12. 
  
 
Figure 4.12 A) On the left IGV visualization; on the right Sanger sequencing electropherogram. The arrow indicates the 
c.1154C>T mutation. B), On the top EYA4 schematic exon representation and on the bottom protein domains: EyaVR 
(Eya-variable region) and Eya HR (Eya-homologous region). The EYA4 mutation is localized in exon 13 on the EYA HR 
domain. C) Multiple alignments of the EYA4 protein aminoacid sequence among species. Ser385 is squared in red. 
 
Segregation analysis was performed on gDNA samples of the proband and other hearing-impaired 
family members, who also underwent a complete audiological and clinical phenotype evaluation. 
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The proband’s grandmother (I-2) was a 67-year-old woman affected by profound hearing loss with 
post-lingual onset and progressive course. She also reported unspecified familial HL, although no 
other affected members of her family were available for the study. The 74-year-old grandfather (I-1) 
had congenital profound hearing loss, brilliant blue eyes, no facial dysmorphic features and was 
referred as having precocious white hair with a white forelock. The 39-year-old uncle (II-3) had 
congenital profound hearing loss, brilliant blue eyes, facial dysmorphisms (dystopia canthorum, 
downslanting palpebral fissures and malar hypoplasia) and pigmentary alterations, among which 
partially white eyebrows and early white hair with referred white forelock. These individuals (I-1 and 
II-3) who clearly met major diagnostic criteria for Waardenburg syndrome type 1 according to the 
WS Consortium criteria [58], had not been previously diagnosed or offered appropriate molecular 
testing. 
Based on the clinical evaluations we proceeded with PAX3 gene testing in the two subjects with WS1 
phenotype (I-1 and II-3) together with segregation analysis of the EYA4 variant.  
The proband (III-1), her father (II-2), her uncle (II-1) and grandfather (I-1) were all found to be 
heterozygote for the EYA4 mutation, while the grandmother (I-2), was negative. 
Comprehensive molecular and clinical data for all the family-member are summarized in Table 4.8. 
 
   Phenotype Genotype 
Pedigree 
position 
Gender Age HL Onset Severity WS signs EYA4 PAX3 
I-1 M 74 congenital profound blu eyes c.1154C>T; p.Ser385Leu c.321+1G>A 
I-2 F 67 post-lingual profound // // // 
II-2 M 42 post-lingual profound // c.1154C>T; p.Ser385Leu // 
II-3 M 39 congenital profound blu eyes, 
dystopia 
cantorum 
c.1154C>T; p.Ser385Leu c.321+1G>A 
III-1 F 9 post-lingual mild // c.1154C>T; p.Ser385Leu // 
 
Table 4.8 Summary of phenotypic features and genotypes.  M: male; F: female. Age of the subjects at evaluation. WS 
indicates Waardenburg syndrome. The symbol // indicates absence of WS clinical signs or mutation. 
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The entire coding sequence of the PAX3 gene was analyzed in individuals I-1 and II-3 with Sanger 
sequencing, as described previously. A novel splice-site mutation NM_181459.3: c.321+1G>A was 
identified in these subjects. The mutation, never previously described in literature, nor reported in the 
public databases as ExAC database (http://exac.broadinstitute.org/; last accessed September 2017) or 
gnomAD browser (http://gnomad.broadinstitute.org/; last accessed September 2017). This splicing 
mutation was predicted by Human splicing finder to alter the splice-donor site of PAX3 intron 2 as 
reported in Figure 4.13. 
 
 
Figure 4.13 A) Electropherogram of exon/intron 2 of PAX3 gene. The arrow indicates the c.321+1G>A splice-site 
mutation. B) On the top PAX3 schematic exon representation and on the bottom protein domains: PD (paired domain); 
o (octapeptide motif); HD (homeodomain); TD (transactivation domain). The PAX3 mutation is located in intron 2. 
 
The novel EYA4 mutation detected by targeted NGS approach in the proband (III-1) could be 
responsible for the type of hearing loss she presented and, with obvious age differences, seemed to 
be typical of the audiological history reported for her father.  
At the clinical evaluation, the 42-year-old proband’s father, whose hearing loss was post-lingual, with 
referred onset before the age of 10, was found to be profoundly deaf. The proband, 9-year-old at the 
time of evaluation, also had post-lingual hearing loss that was measured as mild and still prevalently 
involving mid frequencies.  
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A novel PAX3 splice-site mutation was identified in the affected uncle (II-3) and grandfather (I-1) of 
the proband, both of whom had WS1 phenotype never previously investigated. 
These two subjects also carried the familial EYA4 mutation, but the milder clinical manifestations and 
the progressive course of the DFNA10 phenotype had obviously been masked by the effect of the 
novel PAX3 gene splice-site mutation, which by itself is the likely cause of their congenital profound 
hearing impairment [59] (Appendix 3).   
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5. DISCUSSION 
 
Hearing loss is a highly heterogeneous condition, challenging both from a clinical and genetic 
standpoint. The cause of non-syndromic sensorineural deafness can be extremely difficult to 
investigate based on solely clinical data, especially when the hearing loss is pre-lingual and profound.  
On the other hand, a deafness syndrome can be caused by alterations in different genes and different 
mutations in the same gene may result both in SHL and NSHL [60]. Finally, a specific genetic cause 
may present with extremely variable phenotypic expression, even within members of the same family 
[61], and often the same gene can sustain both dominant and recessive conditions.  
In this study, a highly selected targeted panel approach was decided with the aim of developing a 
translational tool with high diagnostic relevance for NSHL and for some forms of SHL with onset as 
isolated HL, such as Pendred and Usher syndrome. In these conditions, the earlier age of onset of the 
hearing loss versus other later clinical manifestations may be the cause of diagnostic pitfalls or late 
diagnoses. In young individuals, these disorders may be therefore clinically indistinguishable from 
isolated hearing loss but, in view of possible later complications, especially the loss of vision in Usher 
syndrome, an early etiological diagnosis is absolutely essential for a proper clinical follow-up and the 
establishment of adequate rehabilitation strategies. 
The rationale for the choice of a targeted strategy to comprehensively investigate the genetic bases of 
hereditary hearing loss lies in several levels of considerations: first of all, the genetic heterogeneity 
of the condition as a whole, even though within an apparently manageable number of disease-causing 
or highly candidate disease genes.  
The use of other NGS approaches, namely whole genome or whole exome sequencing, would give 
the possibility of including in the analysis a much higher number of genes, and even noncoding 
sequences, versus the limited number of genes in the targeted approach. Obviously, a targeted panel 
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would have the disadvantage of not accounting for new genes possibly found to be responsible of HL, 
which should eventually be accordingly implemented.  
The advantages of the number of genes and sequences though need to be weighed against the 
difficulties of data analysis and variants interpretation, the risk of unsolicited or incidental findings 
and, ultimately but not less importantly, the lower depth of coverage that these latter approaches offer. 
A comprehensive targeted panel puts together all, or a large and highly prioritized set of genes, with 
recognized pathogenic role within the investigated clinical area and guarantees the highest coverage 
of any sequence of interest that may have been introduced.  
A targeted panel may combine advantageous features of the different NGS strategies and may 
therefore result more efficient and actionable.  
 
The Ion Torrent PGM was considered the NGS ideal platform both for its innovative sequencing 
chemistry and for technical features that respond to the needs of a single laboratory.  
Developing a comprehensive NGS targeted panel is a rather demanding process which essential pre-
requirement is a solid clinical knowledge about the disorders to be studied. A series of different steps 
should take place, going from literature interrogation and intense datamining to gene prioritization, 
in which expression, function, networking and “omic” aspects of each gene need to be examined in 
depth. 
The process of gene-selection we undertook was performed also according to evidences of 
pathogenicity and possible impact on hearing loss in Caucasian individuals, with particular attention 
to early onset conditions. This type of choice was dictated by the characteristics of the population 
sample that would mainly be evaluated during the project, largely Caucasian and of pediatric age. 
An extensive review of the literature and of databases was therefore performed, with a particular 
attention in integrating clinical information with genomic and transcriptomic data. Different 
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bioinformatics tools were exploited for this gene selection phase in which the respective information 
on gene and protein function were compared.  
The 59 genes finally selected accounted for more than 90% of all the deafness-associated mutations 
reported in Caucasian by the literature at the time of gene selection phase. (Deafness Variation 
Database, accessed on May 2015). 
 
The use of targeted gene panel in combination with massive parallel sequencing and a tailored 
bioinformatics pipeline of data analysis, allowed us to identify the genetic cause of hearing loss in 34 
subjects out of the 78 tested in total. The diagnostic yield of the 59-gene panel that we have developed 
reached a value of 43.6%.  
The obtained diagnostic rate is slightly higher than the mean value of 41% reported in studies 
evaluating massive parallel sequencing for hearing loss [62]; in these studies targeted panels 
comprising different number of genes were used to evaluate different population samples. Among 
these studies, those performed in Caucasians or in European populations, report diagnostic rates 
ranging from 83% [31] to 38% [63]. The higher value is nevertheless referred to a population of only 
six samples, while the 38% value refers to 24 samples tested for 34 genes. Currently no studies have 
reported a profile of diagnostic yield on a large Italian cohort. 
In our work 78 Caucasian subjects, mainly from Italy, were tested for 59 highly selected genes, so 
we believe our data may have a greater impact in our population, despite the possibility of having 
missed pathogenic mutations possibly located in genes not included in the panel, since unknown or 
never reported mutated in Caucasians at the time of genes-selection. 
Furthermore, the diagnostic rate we report in our study is higher than the mean value of 33% reported 
in a very large cohort of 1119 samples from deaf individuals subjected to whole exome sequencing 
[33].  
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Taken together these data indicate how our targeted approach allowed to develop a successful 
diagnostic tool and how this tool actually responds to the original purpose of the project. 
 
Despite the estimated frequency for autosomal recessive (75-80%) and autosomal dominant (20%) 
HL, 52.9 % of positive subjects of our cohort carried biallelic mutations in autosomal recessive genes, 
while 47.1% were heterozygotes for mutations in autosomal dominant genes. Our interpretation of 
the relatively high number of dominant cases is a possible selection bias, which might depend on the 
easier recruitment of cases with obvious familial transmission versus apparently sporadic cases in 
prevalently small families.  
 
We found in the tested population a high number of subjects carrying only one likely causative variant 
in genes associated with recessive forms of HL (41.2%). This higher carrier frequency in subjects 
with hearing loss with respect to control populations is an interesting observation common to other 
studies [64].  
Among the possible causes of this higher carrier rate could be a non-optimal overall coverage of some 
genes (i.e. ESPN, P2RX2) due to the difficulty of the AmpliSeq Designer to design amplicons; despite 
we filled the gaps with Sanger Sequencing in cases in which a recessive form of hearing loss was 
suspected and only one mutation was identified in a gene, and so we actually covered the whole 
sequence, we didn’t found any likely causative mutations these heterozygotes. 
These data open new perspectives on the research of other molecular mechanism that could be 
responsible of HL. Considering that one of the limits of targeted gene approach is the difficult to 
investigate gene deletions/duplications or chromosome rearrangements, it could be useful to integrate 
different technologies to obtain a more comprehensive information. Other mechanisms that could 
underlie the “missed” mutation data and that represent a future challenge for genomics studies are 
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non-coding sequence variants that could possibly alter intronic regions or regulatory elements or the 
presence of mutations in related genes sustaining a digenic inheritance.  
 
All the variants identified in the course of the study were collected in an in-house database that 
became an invaluable tool for the identification of recurrent or novel variants, with their relative 
information (e.g. allele frequency, frequency in healthy population as reported in 1000 Genomes 
database, dbSNP accession number and in silico pathogenic prediction), for the identification of 
possible alignment errors, and for further stratification and correlation between genotype and 
phenotype. The local database also collects fundamental information about Sanger validation of 
detected variants and about family segregation analysis.  
The database, developed by our laboratory, permits to evaluate the mutation’s frequency among the 
cohort of selected subjects, prevalently Caucasians and mainly of developmental age, and it can be 
used to assess epidemiological data in our population.  
 
In the overall, among the unique variants identified, 871 had a coverage higher than 20X; which was 
the lower cut-off established for the study; of these 448 had an “rs accession number” reported in 
dbSNP.   
After the accurate filtration process and data analysis, 43 variants were actually classified as likely 
causative, 41.8% of which were novel (18/43), i.e. never described in literature, nor present in the 
public databases of healthy population or disease-specific cohorts. An integrated combination of nine 
in silico predictor tools that evaluate the type of aminoacid change and the aminoacid conservation 
among species was used to characterize each detected variant. The InterVar tool was also used to 
classify variants according to the criteria recommended by the ACMG guidelines and establish their 
patogenicity and it was also possible to adjust the parameters according to information on segregation 
analysis. 
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It is interesting to note that only 8 of the variants which we have actually been able to classify as 
disease-associated were already reported in the ClinVar database as pathogenic or likely pathogenic. 
All the novel pathogenic variants and the associated phenotypes will be submitted to the public 
databases in order to contribute to a better knowledge about the genetic bases of hearing loss. 
 
The likely causative variants were found to alter the following genes included in the panel: CDH23, 
GJB2, COCH, MYO7A, ADGRV1, EYA4, OTOG, SLC17A8, TMPRSS3, ACTG1, CEACAM16, 
COL11A2, GJB3, KCNQ4, MYH9, MYO6, PTPRQ, SLC26A4, STRC, TMC1. The fact that only 33% 
of the total number of tested genes was found to harbor mutations could represent an epidemiological 
information given we have mainly tested a population from the North-East part of Italy, although a 
larger study would be necessary to confirm our results.   
 
Among the patogenic variants identified, we found four GJB2 mutations, that had been previously 
missed by Sanger sequencing analysis, either due to PCR technical limits or to the low sensitivity of 
Sanger sequencing in comparison with the NGS technology. 
 
The most frequently mutated gene in our selected cohort was CDH23, which was found altered in 8 
patients with 13 different pathogenic variants, of which 3 novel SNVs.  
Even if the high frequency of CDH23 gene mutations was already reported in two large Japanese 
cohorts [65] [66], our data for the first time report such a high number of mutations in CDH23, in a 
Caucasian cohort,  resulting in a frequency of 23.5% (8/34). 
In this work, seven individuals, compound heterozygote for CDH23 mutations, presented NSHL 
prevalently characterized by post-lingual, moderate to profound hearing loss, consistently with what 
reported in the OMIM database and in literature for the DFNB12 phenotype (OMIM # 601386).  
One subject presented Usher syndrome type 1D (OMIM # 601067). 
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For all the subjects with CDH23 variants, it was possible to perform genotype-phenotype correlation 
that was compared and found to be consistent with the pertinent literature.  
Two of the pathogenic CDH23 mutations were detected in two sisters with sensorineural non-
syndromic peri-lingual bilateral HL, without other symptoms. We identified, in these subjects, a 
known non-synonymous SNV and a novel splice-site variant of which we characterized the precise 
pathogenic mechanism in vitro and demonstrated to cause a complete exon-skipping. 
We were able to substantiate with molecular data a suspect of Usher syndrome in a young child, who 
presented with bilateral congenital profound HL and suggestive early retinal alterations. Given the 
young age of the boy, the early identification of two splice-site pathogenic mutations of CDH23 gene 
represented an extremely important prognostic information for the planning of a proper clinical 
follow-up and future audiological and clinical management as well as for the fundamentally important 
genetic counseling in the family.  
 
We have also been able to establish a straightforward genotype-phenotype correlation in the case of 
a woman, born from consanguineous parents, who presented with bilateral sensorineural profound 
post-lingual hearing loss, with referred onset at 10 years of age, and vestibular dysfunctions. A novel 
PTPRQ homozygous splice-site mutation was detected in her DNA. This finding contributes to 
expanding the so far limited list of known pathogenic variants of this gene. Furthermore, we could 
confirm, based on the phenotype of the proband and the data reported in the OMIM database and in 
literature (DFNB84A, OMIM # 613391), a consistent genotype-phenotype correlation. 
 
Our work also gave us the possibility of disentangling a complicate pattern of transmission in a 
deafness family with many affected members, as reported in section 4.5.4. 
In this family, we observed the occurrence of assortative or non-random mating by deafness state, a 
well-documented condition in which deaf individuals partner together. Due to the known wide genetic 
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heterogeneity in hearing loss, assortative mating increases the likelihood of co-segregation of two or 
more distinct forms of deafness in the same family [18].  
In the family we describe, two novel mutations in different deafness genes, EYA4 (DFNB10) and 
PAX3, causing respectively non-syndromic and syndromic autosomal dominant HL were identified. 
A dual molecular diagnosis was obtained since these mutations, one of which explained the non-
syndromic hearing loss of a father and his daughter, were found to co-occur in two other relatives 
showing a previously misdiagnosed Waardenburg syndrome type 1 phenotype that clearly masked 
the expected DFNA10 audiological profile. 
Until now only 7 DFNA10 families have been reported in literature [67] and variable audiogram 
configurations have been described. Nevertheless, most of the individuals carrying heterozygous 
missense mutations in the EYA4 gene show bilateral, progressive sensorineural hearing loss with 
variable age of onset ranging between the pre-lingual period to slightly over 50 years of age.  DFNA10 
typically involves mid frequencies at onset and progresses thereafter to affect all the frequencies [68]. 
Since one of the main features of the DFNA10 phenotype is progression, precocious identification of 
the EYA4 mutation had a very relevant impact both for the prognosis and for the program of clinical 
follow-up of the young girl we describe.  
Heterozygous mutations in the PAX3 gene associate with a very variable phenotype, as in the case of 
the family described in this work. The individuals we report had in fact both congenital profound 
hearing loss and brilliant blue eyes, but facial dysmorphic features were present only in one subject. 
The milder clinical manifestations and the progressive course of the DFNA10 phenotype caused by 
the EYA4 mutation they were also carrying, had obviously been masked by the effect of the novel 
PAX3 gene splice-site mutation, which by itself is the likely cause of their congenital profound 
hearing impairment. 
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The targeted gene panel approach that we developed proved to be a very useful tool in a diagnostic 
setting for hearing loss due to its many advantages, such as high coverage of targeted regions, high 
throughput and straightforward bioinformatics data analysis and lower costs with respect to single 
gene sequencing,  
Our work demonstrates how the combination of a highly efficient NGS technology, accurate gene-
selection and consistent bioinformatics analysis, coupled with a thorough clinical evaluation allows 
to efficiently investigate the molecular causes of deafness. This integrated approach provides, 
together with a better genetic counseling and risk of recurrence for each affected individual, extremely 
important prognostic and follow-up information for a better and more precise audiological 
management of individuals with hearing loss. The integration of advanced technology and 
bioinformatics knowledge within the modern process of clinical reasoning is at the base of the new 
era of personalized medicine.   
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Appendix 1 
Table 1. List of syndromic forms of hearing loss 
Syndrome Gene Protein OMIM 
Alport Syndrome COL4A5 Collagen, type IV, alpha 5 303630 
COL4A3 Collagen, type IV, alpha 3 120070 
COL4A4 Collagen, type IV, alpha 4 120131 
Branchio-oto-renal Syndrome EYA1 Eyes absent homolog 1 601653 
SIX5 Homeobox protein SIX5 600963 
SIX1 Homeobox protein SIX1 601205 
CHARGE Syndrome SEMA3E Semaphorin 3E 608166 
CHD7 Chromodomain-helicase-DNA-binding protein 7 608892 
Jervell&Lange-Nielsen Syndrome KCNQ1 Potassium channel, voltage gated KQT-like subfamily 
Q, member 1 
607542 
KCNE1 Potassium channel, voltage gated subfamily E 
regulatory beta subunit 1 
176261 
Norrie Disease NDP Norrie disease protein 300658 
Pendred Syndrome SLC26A4 Pendrin 605646 
FOXI1 Forkhead box protein I1 ATP-sensitive inward rectifier 601093 
KCNJ10 Potassium channel 10 602208 
Stickler Syndrome COL2A1 Collagen, type II, alpha-1 120140 
COL11A1 Collagen, type XI, alpha-1 120280 
COL11A2 Collagen, type XI, alpha-2 120290 
COL9A1 Collagen, type IX, alpha-1 120210 
COL9A2 Collagen, type IX, alpha-2 120260 
Treacher Collins Syndrome TCOF1 Treacher Collins-Franceschetti syndrome 1 606847 
POLR1D Polymerase I Polypeptide D 613715 
POLR1C Polymerase I Polypeptide C 610060 
Usher Syndrome MYO7A Myosin VIIA 276903 
USH1C Harmonin 605242 
CDH23 Cadherin 23 605516 
PCDH15 Protocadherin 15 605514 
SANS Scaffold protein containing ankyrin repeats and sam 
domain 
607696 
CIB2 Calcium and integrin binding protein 2 605564 
USH2A Usherin 608400 
VLGR1 Very large G-coupled protein receptor isoform b 602851 
WHRN Whirlin 607928 
CLRN1 Clarin 1 606397 
HARS Histidyl tRNA synthetase 142810 
PZDZ7 PDZ domain containing 7 NA 
CEP250 250 NA 
Waardenburg Syndrome PAX3 Paired box 3 606567 
SNAI2 Snailhomolog 2 602150 
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EDN3 Endothelin 3 131242 
EDNRB Endothelin receptor type B 131244 
MITF Microphthalmia-associated transcription factor 156845 
SOX10 SRY box10 602229 
Perrault Syndrome HSD17B4 Hydroxysteroid (17-beta) dehydrogenase 4 601860 
HARS2 Histidyl-TRNA Synthetase 2 600783 
CLPP Caseinolytic mitochondrial matrix peptidase 
proteolytic subunit 
601119 
LARS2 Leucyl-tRNA synthetase2 604544 
 
Genes and proteins involved in SHL with specific OMIM number. NA: not available. 
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Appendix 2 
Table 2. List of genes related to NSHL 
Mode of inheritance Locus Gene Protein 
AD NA CRYM Crystallin, Mu 
AD DFNA1 DIAPH1 Diaphanous 1 
AD DFNA2A KCNQ4 KCNQ4 
AD DFNA2B GJB3 (Cx31) Connexin 31 
AD DFNA3A GJB2 (Cx26) Connexin 26 
AD DFNA3B GJB6 (Cx30) Connexin 30 
AD DFNA4 MYH14 Nonmuscle myosin heavy chain XIV 
AD DFNA4 CAECAM16 Carcinogenic antigen-related cell adhesion molecule 16 
AD DFNA5 DFNA5 Gasdermin E 
AD DFNA6/14/38 WFS1 Wolframin 
AD DFNA8/12 TECTA A-tectorin 
AD DFNA9 COCH Cochlin 
AD DFNA10 EYA4 Eyes absent 4 
AD DFNA11 MYO7A Myosin VIIa 
AD DFNA13 COLL11A2 Type XI collagen α2 
AD DFNA15 POU4F3 Class 3 POU 
AD DFNA17 MYH9 Nonmuscle myosin heavy chain IX 
AD DFNA20/26 ACTG1 γ-actin 
AD DFNA22 MYO6 Myosin VI 
AD DFNA23 SIX1 Sine Oculis Homeobox, Drosophila, homolog of,1 
AD DFNA25 SLC17A8 VGLUT-3 
AD DFNA28 GRHL2 Grainyhead-like 2 
AD DFNA36 TMC1 Transmembrane channel-like protein 1 
AD DFNA41 P2RX2 Purinergic receptor P2X ligand-gated ion channel 2 
AD DFNA44 CCDC50 Coiled-coil domain-containing protein 50 
AD DFNA50 MIR96 MicroRNA96 
AD DFNA51 TJP2 Tight junction protein 2 
AD DFNA56 TNC Tenascin-C 
AD DFNA64 SMAC/DIABLO Second Mitochondria-Derived Activator of 
Caspase/Direct Inhibitor of Apoptosis protein Binding 
protein with a low pI 
AD DFNA65 TBC1D24 Tbc1 domain family, member 24 
AD DFNA66 CD164 Cd164 Antigen 
AD DFNA67 OSBPL2 Oxysterol-binding Protein-like Protein 2 
AD NA HOMER2 Homer, drosophila, homolog of 2 
AD NA MCM2 Minichromosome maintenance complex component 
AD NA KITLG Kit ligand 
AD NA DMXL2 Dmx-like 2 
AR DFNB1A GJB2 (Cx26) Connexin 26 
AR DFNB1B GJB6 (Cx30) Connexin 30 
AR DFNB2 MYO7A Myosin VIIa 
AR DFNB3 MYO15A Myosin Xva 
AR DFNB4 SLC26A4 Pendrin 
AR DFNB6 TMIE Transmembrane inner ear-expressed gene 
AR DFNB7/11 TMC1 Transmembrane channel-like protein 1 
AR DFNB8/10 TMPRSS3 Transmembrane protease, serine 3 
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AR DFNB9 OTOF Otoferlin 
AR DFNB12 CDH23 Cadherin 23 
AR DFNB15/72/95 GIPC3 GIPC PDZ domain-containing family member 3 
AR DFNB16 STRC Stereocilin 
AR DFNB18 USH1C Harmonin 
AR DFNB18B OTOG Otogelin 
AR DFNB21 TECTA α-tectorin 
AR DFNB22 OTOA Otoancorin 
AR DFNB23 PCDH15 Protocadherin 15 
AR DFNB24 RDX Radixin 
AR DFNB25 GRXCR1 Glutaredoxin, cysteine-rich 1 
AR DFNB28 TRIOBP Trio-binding protein 
AR DFNB29 CLDN14 Claudin 14 
AR DFNB30 MYO3A Myosin IIIa 
AR DFNB31 WHRN Whirlin 
AR DFNB35 ESRRB Oestrogen-related receptor β 
AR DFNB36 ESPN Espin 
AR DFNB37 MYO6 Myosin VI 
AR DFNB39 HGF Hepatocyte growth factor 
AR DFNB42 ILDR1 Immunoglobulin-like domain containing receptor 1 
AR DFNB44 ADCY1 Adenylate cyclase 1 
AR DFNB48 CIB2 Calcium and integrin binding protein 2 
AR DFNB49 MARVELD2 Tricellulin 
AR DFNB49 BDP1 B-double prime 1, subunit of RNA polymerase III 
transcription initiation factor 
AR DFNB53 COL11A2 Type XI collagen α2 
AR DFNB59 PJVK DFNB59 gene 
AR DFNB60 SLC22A4 Solute carrier family 22 (organic cation transporter) 
AR DFNB61 SLC26A5 Prestin 
AR DFNB63 LRTOMT/COMT2 Leucine rich transmembrane o-methlytransferase 
AR DFNB67 LHFPL5 Tetraspan membrane protein 
AR DFNB68 S1PR2 Sphingosine -1 phosphatase receptor 2 
AR DFNB70 PNPT1 Polyribonucleotide nucleotidytransferase 1 
AR DFNB73 BSND Barttin 
AR DFNB74 MSRB3 Methionine sulfoxide reductase B3 
AR DFNB76 SYNE4 Spectrin repeat-containing nuclear envelope protein 4 
AR DFNB77 LOXHD1 Lypoxygenase homology domain containing 1 
AR DFNB79 TPRN Taperin 
AR DFNB82 GPSM2 G-protein signaling modulator 2 
AR DFNB84 PTPRQ Protein tyrosine phosphate receptor Q 
AR DFNB84 OTOGL Otogelin like protein 
AR DFNB86 TBC1D24 Tbc1 domain family, member 24 
AR DFNB88 ELMOD3 Elmo/CED12 domain-containing protein 3 
AR DFNB89 KARS Lysyl-tRNA synthetase 
AR DFNB91 SERPINB6 Serpin Peptidase inhibitor clade B, member 6 
AR DFNB93 CABP2 Calcium-binding protein 2 
AR DFNB94 NARS2 Asparaginyl-tRNA synthetase 2 
AR DFNB97 MET MET protooncogene 
AR DFNB98 TSPEAR Thrombospondin-type laminin g domain and ear repeats 
AR DFNB99 TMEM132E Transmembrane protein 132e 
AR DFNB101 GRXCR2 Glutaredoxin, cysteine-rich 2 
88 
 
AR DFNB102 EPS8 Epidermal growth factor receptor pathway substrate 8 
AR DFNB103 CLIC5 Chloride intracellular channel 5 
AR DFNB105 CDC14A Cell division cycle 14, S. Cerevisiae homolog A 
AR NA FAM65B Family with sequence similarity 65, member b 
AR NA EPS8L2 EPS8-like protein 2 
AR NA WBP2 WW Domain binding protein 2 
AR NA ROR1 Receptor tyrosine kinase-like orphan receptor 1  
X-linked DFNX1 PRPS1 Phosphoribosylpyrophosphate synthetase 1 
X-linked DFNX3 POU3F4 Class 3 POU 
X-linked DFNX4 SMPX Small muscle protein X-linked 
X-linked DFNX5 AIFM1 Apoptosis-inducing factor, mitochondria-associated, 1 
X-linked DFNX6 COL4A6 Collagen, type IV, alpha-6 
 
List of NSHL genes from Hereditary Hearing Loss Homepage. (http://hereditaryhearingloss.org/; last accessed October 
2017). AD: autosomal dominant; AR: autosomal recessive; NA: not available. 
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